Onconetix Q3 2026 net loss widens to $31.6M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Onconetix, Inc. (ONCO) reported revenue of $102,884 for the three months ended September 30, 2026, versus $303,651 a year earlier; nine-month revenue was $141,461 versus $511,775. Quarterly net loss was $31,627,931, compared with $8,783,702, including a $30,391,400 noncash ELOC commitment fee. Nine-month net loss was $38,710,109 versus $19,702,029.
Cash was $2,741,657 at September 30, 2026, and operations used $5,758,516 during the first nine months. Management said recurring losses and lack of sustained positive cash flow raise substantial doubt about ONCO's ability to continue as a going concern within one year from issuance. Under the proposed Realbotix acquisition, if closing Net Cash is below $12.5 million and the parties proceed, the seller would own 95% of fully diluted shares. The July 2026 equity line gives ONCO the right, but not the obligation, to sell up to $750,000,000 of common stock, subject to limitations. ONCO effected a one-for-ten reverse stock split on November 6, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointOperating cash used fell to $5,758,516 from $6,587,805 in the nine-month periods.
Negative
- Major pointQuarterly net loss widened from $8,783,702 to $31,627,931.
- Major pointManagement cited substantial doubt about going concern within one year.
- Moderate pointQuarterly revenue fell to $102,884 from $303,651 year over year.
- Minor pointNine-month revenue fell to $141,461 from $511,775 year over year.
- Minor pointThe noncash ELOC commitment fee expense was $30,391,400 in the third quarter.
Filing Explained
Onconetix paid the $30 million equity-line fee in convertible preferred stock, fully earned at closing; no line shares had been sold by September 30.
The July 2026 equity-line commitment was compensated with Series F preferred shares, which remained outstanding at quarter-end and are convertible into common stock; any resulting new shares increase the share count and reduce existing holders’ percentage ownership absent offsets.
Before stockholder approval, the conversion price cannot fall below
At
The Series F shares had a
Key Figures
Key Terms
going concern financial
equity line of credit financial
noncash expense financial
embedded derivative liability financial
Level 3 inputs financial
Net Cash financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were ONCO's third-quarter 2026 revenue and net loss?
What limits apply to ONCO's $750 million equity line?
Does ONCO's Realbotix note bear interest?
What happens to ONCO's Realbotix note if the Share Exchange closes?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
OR
For the transition period from to
Commission File Number:
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No
As of November 10, 2026, the registrant had
TABLE OF CONTENTS
| Page | ||
| Cautionary Note Regarding Forward-Looking Statements | ii | |
| PART I. | FINANCIAL INFORMATION | 1 |
| Item 1. | Condensed Consolidated Financial Statements (unaudited) | 1 |
| Condensed Consolidated Balance Sheets | 1 | |
| Condensed Consolidated Statements of Operations and Comprehensive Loss | 2 | |
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) | 3 | |
| Condensed Consolidated Statements of Cash Flows | 4 | |
| Notes to Unaudited Condensed Financial Statements | 5 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 31 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 47 |
| Item 4. | Controls and Procedures | 47 |
| PART II. | OTHER INFORMATION | 49 |
| Item 1. | Legal Proceedings | 49 |
| Item 1A. | Risk Factors | 49 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 49 |
| Item 3. | Defaults Upon Senior Securities | 49 |
| Item 4. | Mine Safety Disclosures | 49 |
| Item 5. | Other Information | 49 |
| Item 6. | Exhibits | 50 |
| Signatures | 51 | |
i
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements that reflect our current expectations and views of future events. The forward-looking statements are contained principally in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Readers are cautioned that known and unknown risks, uncertainties and other factors, including those over which we may have no control and others listed in the “Risk Factors” section of this Report, may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these words. These statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance, or achievement to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements include, but are not limited to, statements about:
| ● | our projected financial position and estimated cash burn rate; |
| ● | our estimates regarding expenses, future revenues and capital requirements; |
| ● | our ability to continue as a going concern; |
| ● | our need to raise substantial additional capital to fund our operations and repay indebtedness; |
| ● | our ability to commercialize or monetize Proclarix and integrate the assets and commercial operations acquired in the share exchange with Proteomedix AG (“Proteomedix”); |
| ● | our reliance on third parties, including Laboratory Corporation of America (“LabCorp”), to develop, market, distribute and sell Proclarix; |
| ● | the successful development of our commercialization capabilities, including sales and marketing capabilities; |
| ● | our ability to consummate the transaction on a timely basis as contemplated by the Share Exchange Agreement with Realbotix, LLC (“Realbotix” and the “Share Exchange Agreement” and the transactions contemplated therein, the “Realbotix Transaction”) and the anticipated benefits of the Realbotix Transaction; |
| ● | our ability to maintain the necessary regulatory approvals to market and commercialize our product; |
| ● | the results of market research conducted by ourselves or others; |
| ● | our ability to obtain and maintain intellectual property protection for our current products; |
| ● | our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights; |
ii
| ● | the possibility that a third party may claim we or our third-party licensors have infringed, misappropriated, or otherwise violated their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against claims against us; |
| ● | our reliance on third parties, including manufacturers and logistics companies; |
| ● | the success of competing therapies or diagnostics and products that are or become available; |
| ● | our ability to successfully compete against current and future competitors; |
| ● | our ability to expand our organization to accommodate potential growth and our ability to attract, motivate and retain key personnel; |
| ● | the potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for these product liability lawsuits to cause us to limit our commercialization of our product; |
| ● | market acceptance of our product, the size and growth of the potential markets for our current product, and our ability to serve those markets; and |
| ● | disruptions in the business of Onconetix or Proteomedix, which could have an adverse effect on their respective businesses and financial results. |
These forward-looking statements involve numerous risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results of operations or the results of other matters that we anticipate herein could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our expectations are generally set forth in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and other sections in this Report. You should thoroughly read this Report and the documents that we refer to with the understanding that our actual future results may be materially different from and worse than what we expect. We qualify all our forward-looking statements by these cautionary statements.
The forward-looking statements made in this Report relate only to events or information as of the date on which the statements are made in this Report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this Report and the documents that we refer to in this Report and have filed as exhibits to this Report, completely and with the understanding that our actual future results may be materially different from what we expect.
iii
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
ONCONETIX,
INC.
Condensed Consolidated Balance Sheets
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Inventories | ||||||||
| Notes receivable | — | |||||||
| Investor receivable | — | |||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Deferred offering costs | ||||||||
| Operating right of use asset | ||||||||
| Goodwill | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Notes payable | — | |||||||
| Operating lease liability, current | ||||||||
| Contingent warrant liabilities | ||||||||
| Derivative liabilities | ||||||||
| Total current liabilities | ||||||||
| Operating lease liability, net of current portion | ||||||||
| Total liabilities | $ | $ | ||||||
| Commitments and Contingencies | ||||||||
| Series C Redeemable Preferred Stock, $ | ||||||||
| Series F Redeemable Preferred Stock, $ | — | |||||||
| Stockholders’ equity | ||||||||
| Common stock, $ | — | |||||||
| Series D Preferred Stock, $ | — | — | ||||||
| Series E Preferred Stock, $ | — | — | ||||||
| Additional paid-in capital | ||||||||
| Treasury stock, at cost; | ( | ) | ( | ) | ||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Total stockholders’ equity (deficit) | ( | ) | ||||||
| Total liabilities, convertible preferred stock, and stockholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
1
ONCONETIX,
INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | $ | $ | $ | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general, and administrative | ||||||||||||||||
| Research and development | ( | ) | ( | ) | ||||||||||||
| Impairment of goodwill | — | — | ||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other (expense) income | ||||||||||||||||
| Loss on extinguishment of note payable | — | ( | ) | — | ( | ) | ||||||||||
| Loss on issuance of preferred stock and warrants | — | ( | ) | — | ( | ) | ||||||||||
| Loss on extinguishment of preferred stock | — | ( | ) | — | ( | ) | ||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Change in fair value of subscription agreement liability – related party | — | — | — | |||||||||||||
| Change in fair value of contingent warrant liabilities | ( | ) | ( | ) | ( | ) | ||||||||||
| Change in fair value of Series D Derivative Liability | ( | ) | ( | ) | ||||||||||||
| Change in fair value of Series E Derivative Liability | — | — | — | |||||||||||||
| Change in fair value of Series F Derivative Liability | — | — | ||||||||||||||
| Change in fair value of Series D Warrant Liability | — | — | ||||||||||||||
| ELOC commitment fee | ( | ) | — | ( | ) | — | ||||||||||
| Gain on forgiveness of accounts payable | — | — | — | |||||||||||||
| Other income (loss) | ( | ) | ( | ) | ||||||||||||
| Total other income (loss) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Deemed dividend Series C preferred stock | — | — | — | ( | ) | |||||||||||
| Net loss applicable to common stockholders | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss per share, basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of common shares outstanding, basic and diluted | ||||||||||||||||
| Other comprehensive income (loss) | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Foreign currency translation | ( | ) | ( | ) | ( | ) | ||||||||||
| Change in pension benefit obligation | — | — | ||||||||||||||
| Total comprehensive loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2
ONCONETIX, INC.
Condensed Consolidated Statements of Convertible Preferred Stock and
Stockholders’
Equity (Deficit)
(Unaudited)
| Series D Preferred Stock | Common Stock | Additional Paid-in |
Treasury Stock | Accumulated | Accumulated Other Comprehensive | Due from | Total Stockholders’ | |||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Shares | Amount | Deficit | Income | Shareholders | Equity | ||||||||||||||||||||||||||||||||||
| Balance at December 31, 2024 | — | $ | — | $ | — | $ | — | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||||||
| Issuance of common stock in connection with the ELOC | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Redemption of Series C Preferred Stock | — | — | — | — | — | — | — | ( | ) | — | — | ( | ) | |||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Change in pension benefit obligation | — | — | — | — | — | — | — | — | ( | ) | — | ( | ) | |||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | ( | ) | — | — | ( | ) | |||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | — | $ | — | $ | — | $ | — | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | — | $ | |||||||||||||||||||||||||
| Issuance of common stock in connection with the ELOC | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Cash in lieu of shares | — | — | — | — | ( | ) | — | — | — | — | — | ( | ) | |||||||||||||||||||||||||||||||
| Redemption of Series C Preferred Stock | — | — | — | — | — | — | — | ( | ) | — | — | ( | ) | |||||||||||||||||||||||||||||||
| Settlement of subscription agreement liability | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Change in pension benefit obligation | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | ( | ) | — | — | ( | ) | |||||||||||||||||||||||||||||||
| Balance at June 30, 2025 | — | $ | — | $ | — | $ | — | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | — | $ | |||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Issuance of restricted common stock | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Issuance of Series D Preferred Stock | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| Conversion of Series C Preferred shares to common stock | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| Exchange of Series C Preferred Stock to Series D Preferred Stock | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| Conversion of Series D Preferred Stock to common stock | ( | ) | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Cancellation of restricted common stock | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | — | — | — | — | — | — | — | — | ( | ) | — | ( | ) | |||||||||||||||||||||||||||||||
| Change in pension benefit obligation | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | ( | ) | — | — | ( | ) | |||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | — | $ | — | $ | — | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | — | $ | ||||||||||||||||||||||||||
| Series D Preferred Stock | Series E Preferred Stock | Common Stock | Additional Paid-in |
Treasury Stock | Accumulated | Accumulated Other Comprehensive | Total Stockholders’ | |||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Shares | Amount | Deficit | Income | Equity | |||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2025 | $ | — | $ | — | $ | — | — | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Conversion of Series E Preferred Stock to Common Stock | — | — | ( | ) | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| Conversion of Series D Preferred Stock to Common Stock | ( | ) | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| Issuance of Common Stock for warrant exercise | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Cancellation of restricted common stock | — | — | — | — | ( | ) | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Cash in lieu of shares | — | — | — | — | — | — | ( | ) | — | — | — | — | ( | ) | ||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | — | — | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | — | ( | ) | — | ( | ) | ||||||||||||||||||||||||||||||||||
| Balance at March 31, 2026 | $ | — | $ | — | $ | — | — | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Issuance of common stock in connection with the ELOC | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Conversion of Series E Preferred Stock to Common Stock | — | — | ( | ) | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Conversion of Series D Preferred Stock to Common Stock | ( | ) | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Cancellation of restricted common stock | — | — | — | — | ( | ) | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Cash in lieu of shares | — | — | — | — | ( | ) | — | ( | ) | — | — | — | — | ( | ) | |||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | — | — | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | — | ( | ) | — | ( | ) | ||||||||||||||||||||||||||||||||||
| Balance at June 30, 2026 | $ | — | — | $ | — | $ | — | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
| Issuance of common stock in connection with the ELOC | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Conversion of Series D Preferred Stock to Common Stock | ( | ) | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Conversion of Series F Preferred Stock to Common Stock | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Cash in lieu of shares | — | — | — | — | ( | ) | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | — | — | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | — | ( | ) | — | ( | ) | ||||||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | — | — | $ | — | $ | — | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
ONCONETIX,
INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Nine Months Ended September 30, 2026 |
Nine Months Ended September 30, 2025 |
|||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Loss on impairment of goodwill | ||||||||
| Amortization of debt discounts | — | |||||||
| Depreciation and amortization | ||||||||
| Net periodic pension benefit | — | |||||||
| Stock-based compensation | ||||||||
| Loss on extinguishment of notes payable | — | |||||||
| Loss on extinguishment of Series C preferred stock | — | |||||||
| Loss on issuance of Series D preferred stock | — | |||||||
| Change in fair value of contingent warrant liabilities | ( | ) | ||||||
| Change in fair value of warrant liabilities | — | ( | ) | |||||
| Change in fair value of subscription agreement liability - related party | — | ( | ) | |||||
| Gain on forgiveness of accounts payable | — | ( | ) | |||||
| Change in fair value of Series D derivative liability | ( | ) | ||||||
| Change in fair value of Series E derivative liability | ( | ) | — | |||||
| Change in fair value of Series F derivative liability | ( | ) | — | |||||
| ELOC Commitment Fee | — | |||||||
| Series F transaction costs | — | |||||||
| Loss on disposal of property and equipment | — | |||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ||||||||
| Inventories | ( | ) | ( | ) | ||||
| Investor receivable | — | |||||||
| Prepaid expenses and other current assets | ( | ) | ||||||
| Deferred offering costs | — | ( | ) | |||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued expenses | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities | ||||||||
| Issuance of note receivable | ( | ) | — | |||||
| Net cash used in investing activities | ( | ) | — | |||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of note payable | ||||||||
| Principal payments of notes payable | ( | ) | ( | ) | ||||
| Payment for redemption of Series C Preferred Stock | — | ( | ) | |||||
| Proceeds from Series F preferred stock issuance | — | |||||||
| Transaction costs - Series F preferred stock issuance | ( | ) | — | |||||
| Proceeds from exercise of warrants | — | |||||||
| Proceeds from issuance of Series D preferred stock and warrants | — | |||||||
| Cash in lieu of shares | ( | ) | ( | ) | ||||
| Proceeds from purchases of common stock in connection with the ELOC | ||||||||
| Net cash provided by financing activities | ||||||||
| Effect of exchange rate changes on cash | ( | ) | ( | ) | ||||
| Net increase (decrease) in cash | ( | ) | ||||||
| Cash, beginning of period | ||||||||
| Cash, end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Noncash investing and financing activities: | ||||||||
| Issuance of Series F preferred stock in exchange for ELOC commitment | $ | — | ||||||
| Recognition of Series F derivative liability | $ | — | ||||||
| Series F transaction costs paid directly from proceeds | $ | — | ||||||
| D&O insurance premium financed | $ | — | $ | |||||
| Deemed dividend owed to Series C preferred stock shareholders | $ | — | $ | |||||
| Settlement of subscription agreement liability | $ | — | $ | |||||
| Conversion of Series D preferred stock to common stock | $ | $ | — | |||||
| Conversion of Series F preferred stock to common stock | $ | $ | — | |||||
| Recognition of warrant liabilities | $ | — | $ | |||||
| Recognition of derivative liabilities | $ | — | $ | |||||
| Recognition of Series D preferred stock | $ | — | $ | |||||
| Series C preferred stock exchanged for Series D preferred stock | $ | — | $ | |||||
| Settlement of note payable through issuance of Series D preferred stock | $ | — | $ | |||||
| Conversion of Series E preferred stock to common stock | $ | $ | — | |||||
| Conversion of Series C preferred stock to common stock | $ | — | $ | |||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
ONCONETIX,
INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 1 — Organization and Basis of Presentation
Organization and Nature of Operations
Onconetix, Inc. (formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.) (the “Company” or “Onconetix”) was formed on October 26, 2018, and is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology.
On December 15, 2023, Onconetix acquired
In April 2023, the Company acquired ENTADFI, a Food and Drug Administration (“FDA”)-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia.
Historically, the Company’s focus was on the research and development of transformational vaccines to prevent infectious diseases worldwide, until the third quarter of 2023, at which time the Company halted its efforts on vaccine development activities to focus on commercialization activities for ENTADFI and pursue other potential acquisitions. However, in light of (i) the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii) the Company’s cash runway and indebtedness, the Company abandoned commercialization of ENTADFI and the ENTADFI assets were fully impaired at June 30, 2024.
On April 21, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from “Blue Water Vaccines Inc.” to “Blue Water Biotech, Inc.” The name change was effective as of April 21, 2023. On December 15, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from “Blue Water Biotech, Inc.” to “Onconetix, Inc.” In connection with each of the name changes, the Company also amended the Company’s bylaws to reflect the new corporate name.
Reverse Stock Split
On March 25, 2026,
On May 21, 2026,
On November 6, 2026, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-ten (1:10). The Company accounted for the reverse stock split on a retrospective basis pursuant to ASC 260, Earnings Per Share. All issued and outstanding common stock, common stock warrants, and share-based awards’ exercise prices and per share data have been adjusted in these consolidated financial statements, on a retrospective basis, to reflect the reverse stock split for all periods presented. The number of authorized shares and par value of the preferred stock and common stock were not adjusted because of the reverse stock split.
Basis of Presentation and Principles of Consolidation
The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of Onconetix and its
5
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 1 — Organization and Basis of Presentation (cont.)
Unaudited Interim Consolidated Financial Statements
The accompanying condensed consolidated balance sheet as of September 30, 2026, and the condensed consolidated statements of operations and comprehensive loss and the condensed consolidated statements of convertible preferred stock and stockholders’ equity (deficit) for the three and nine months ended September 30, 2026 and 2025, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2026 and 2025 are unaudited. These unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, and in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2026 and its results of operations and comprehensive loss for the three and nine months ended September 30, 2026 and 2025, and its cash flows for the nine months ended September 30, 2026 and 2025. The financial data and the other financial information disclosed in the notes to these condensed consolidated financial statements related to the three and nine month periods are also unaudited. Operating results for the three and nine months ended September 30, 2026, are not necessarily indicative of the results that may be expected for the year ended December 31, 2026, any other interim periods, or any future year or period. The unaudited condensed consolidated financial statements included in this Report should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which includes a broader discussion of the Company’s business and the risks inherent therein.
Note 2 — Going Concern and Management’s Plans
The Company’s operating activities to date have been devoted to seeking licenses, engaging in research and development activities, potential asset and business acquisitions, expenditures associated with the previously planned commercial launch of ENTADFI, and the commercialization of Proclarix.
The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future.
As of September 30, 2026, the Company had cash of approximately $
The Company continues to generate recurring net operating losses and has not yet established sustained positive cash flows to support its strategic growth initiatives, which includes the commercialization of Proclarix, and participation in strategic transactions and investments, including its proposed acquisition of Realbotix. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date of the issuance of these consolidated financial statements.
6
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 2 — Going Concern and Management’s Plans (cont.)
Management’s plans for funding the Company’s operations include advancing its strategic initiatives, including commercialization efforts related to Proclarix, and execution of recent and potential strategic transactions, including the proposed transaction with Realbotix.
Management also intends to pursue additional equity or debt financing to support operations and strategic initiatives. The Company has equity line of credit arrangements with two institutional investors, entered in October 2024 and July 2026 of up to $
The Company has entered into a Share Exchange Agreement, dated February 11, 2026, as amended by the First Amendment dated November 4, 2026 (as amended, the “Share Exchange Agreement”), to acquire Realbotix, LLC (“Realbotix”). Under the Share Exchange Agreement, if the Company’s Net Cash (as defined in the Share Exchange Agreement) at closing is less than $
If the Share Exchange Agreement is terminated, the Company may be required to pay a termination fee of $
There can be no assurance that the Realbotix transaction will close, that the Company will have sufficient Net Cash at closing to avoid the increased ownership dilution to existing stockholders described above, or that the Company will be able to fund the costs of the transaction or any termination fee and expense reimbursement that may become payable.
Under the Grid Promissory Note (see Note 4), the Company has funded $
The Company’s Series F preferred stock contains provisions under which the Company could be required to make cash payments. These include:
| ● | Cash in lieu of shares on conversion of the Series F Preferred Stock if the Company does not have sufficient authorized shares of common stock. The cash in lieu is calculated at the highest closing price of the common stock during the settlement period. By way of illustration of the conversion of Series F Preferred Stock and the amount of shares that the Company is required to issue, the conversion of all Series F Preferred Stock at the current floor price of $ |
| ● | Registration delay payments equal to |
| ● | Late-delivery and buy-in payments if conversion shares are not timely delivered. |
If any of these events occurs, the Company may not have sufficient resources to make the required payments, which would materially affect its liquidity and its ability to continue as a going concern.
Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the unaudited condensed consolidated financial statements, which is not alleviated by management’s plans. The unaudited condensed consolidated financial statements have been prepared under the going concern basis of accounting. These unaudited condensed consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.
7
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 3 — Summary of Significant Accounting Policies
During the nine months ended September 30, 2026, there were no changes to the Company’s significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Selected significant accounting policies are discussed in further detail below:
Fair Value Measurements
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
| ● | Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
| ● | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
| ● | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Financial instruments, including cash, notes receivable, accounts receivable, accounts payable, accrued liabilities, operating lease liabilities, and notes payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
The fair value of the contingent warrant liability and Series D, E, and F derivative liabilities are valued using significant unobservable measures and other fair value inputs and are therefore classified as Level 3 financial instruments.
The fair value of financial instruments measured on a recurring basis is as follows as of September 30, 2026 and December 31, 2025:
| As of September 30, 2026 | ||||||||||||||||
| Description | Total | Level 1 | Level 2 | Level 3 | ||||||||||||
| Liabilities: | ||||||||||||||||
| Contingent warrant liabilities | $ | — | — | $ | ||||||||||||
| Series D derivative liabilities | $ | — | — | $ | ||||||||||||
| Series F derivative liabilities | $ | — | — | $ | ||||||||||||
| Total | $ | $ | — | $ | — | $ | ||||||||||
| As of December 31, 2025 | ||||||||||||||||
| Description | Total | Level 1 | Level 2 | Level 3 | ||||||||||||
| Liabilities: | ||||||||||||||||
| Contingent warrant liabilities | $ | — | — | $ | ||||||||||||
| Series D and E derivative liabilities | $ | — | — | $ | ||||||||||||
| Total | $ | $ | — | $ | — | $ | ||||||||||
8
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 3 — Summary of Significant Accounting Policies (cont.)
Notes Receivable and Allowance for Credit Losses
Notes receivable are financial assets carried at amortized cost, which is the unpaid principal balance adjusted for any unamortized discounts, premiums, or deferred fees and costs. Interest income, when applicable, is recognized over the term of the note using the effective interest method. Notes that mature within twelve months of the balance sheet date are classified as current.
The Company measures expected credit losses on notes receivable under ASC 326-20, Financial Instruments – Credit Losses. The allowance for credit losses is a valuation account that reduces the amortized cost basis to the amount the Company expects to collect over the contractual term of the note. Management estimates expected credit losses using relevant information about past events, current conditions, and reasonable and supportable forecasts. This includes the borrower’s financial condition and liquidity, the terms of the note, any guarantees or other credit support, and the expected manner of settlement. Notes that do not share risk characteristics with other financial assets are evaluated individually. Changes in the allowance are recorded in the statement of operations in the period of change. Notes receivable are written off against the allowance when management determines that all or part of the balance is uncollectible, and subsequent recoveries are recognized when received. The Company reassesses its notes receivable and the related allowance each reporting period.
Revenue Recognition
During the three months ended September 30, 2026 and 2025, the Company recognized revenue of approximately $
During the nine months ended September 30, 2026 and 2025, the Company recognized revenue of approximately $
The following is a description of principal activities from which the Company generates its revenue:
Development Services
Proteomedix provides a range of services to life sciences customers referred to as “Development Services” including testing for biomarker discovery, assay design and development. These Development Services are performed under individual statement of work (“SOW”) arrangements with specific deliverables defined by the customer. Development Services are generally performed on a time and materials basis. During the performance and through completion of the service to the customer in accordance with the SOW, the Company has the right to bill the customer for the agreed upon price and recognizes the Development Services revenue over the period estimated to complete the SOW. The Company generally identifies each SOW as a single performance obligation.
Completion of the service and satisfaction of the performance obligation under a SOW is typically evidenced by access to the data or test made available to the customer or any other form or applicable manner of delivery defined in the SOW. However, for certain SOWs under which work is performed pursuant to the customer’s highly customized specifications, the Company has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, the Company recognizes revenue over a period of time during which the work is performed based on the expended efforts (inputs). As the performance obligation under the SOW is satisfied, any amounts earned as revenue and billed to the customer are included in accounts receivable.
Product Sales
The Company derives revenue through sales of its products, which includes Proclarix, its diagnostic product, directly to end users, including laboratories, hospitals, and medical centers, and to distributors. The Company considers customer purchase orders, which in some cases are governed by master sales agreements or standard terms and conditions, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. The Company fulfills its performance obligation applicable to product sales once the product is transferred to the customer.
Other Revenue
The Company generates other revenue including license revenue through agreements that grant third parties rights to use its intellectual property and proprietary materials. In September 2025, the Company entered into a license agreement with Immunovia AB, under which it granted exclusive rights to certain intellectual property and transferred biological materials related to the PancreaSure™ test. The agreement included two non-refundable payments of $
9
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 3 — Summary of Significant Accounting Policies (cont.)
Any revenues earned but not yet billed to the customer as of the date of the condensed consolidated financial statements are recorded as contract assets and are included in prepaid expenses and other current assets in the accompanying condensed consolidated financial statements. The Company had no unbilled accounts receivable as of September 30, 2026 and December 31, 2025. Amounts recorded in contract assets are reclassified to accounts receivable in our condensed consolidated financial statements when the customer is invoiced according to the billing schedule in the contract. Accounts receivable was approximately $
In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred.
New Accounting Pronouncements
There were no new accounting pronouncements issued since the Company’s filing of the Annual Report on Form 10-K for the year ended December 31, 2025, which could have a significant effect on the accompanying condensed consolidated financial statements.
Note 4 — Balance Sheet Details
Inventories
Inventories, which primarily relate to Proclarix product as of September 30, 2026 and December 31, 2025, consisted of the following:
| September 30, 2026 | December 31, 2025 | |||||||
| Raw materials | $ | $ | ||||||
| Finished goods | ||||||||
| Total | $ | $ | ||||||
Note Receivable
Grid Promissory Note and Guaranty of Payment
On September 11, 2026, the Company entered into a promissory note with Realbotix (the “Grid Promissory Note”), under which the Company agreed to lend Realbotix up to $
At the closing of the Share Exchange, the Grid Promissory Note will be automatically cancelled. As amended by the First Amendment dated November 4, 2026 (see Note 14), Net Cash under the Share Exchange Agreement includes the unpaid principal outstanding under the Grid Promissory Note at closing, plus unpaid accrued interest outstanding. If Net Cash at closing is less than $
10
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 4 — Balance Sheet Details (cont.)
Realbotix’s obligations under the Grid Promissory Note are guaranteed by Realbotix Corp. pursuant to a Guaranty of Payment, dated September 11, 2026 (the “Guaranty”).
As of September 30, 2026, the note receivable is carried at its amortized cost of $
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following as of September 30, 2026, and December 31, 2025:
| September 30, 2026 | December 31, 2025 | |||||||
| Prepaid insurance | $ | $ | ||||||
| VAT taxes receivable | ||||||||
| Prepaid other | ||||||||
| Other receivable | ||||||||
| Total | $ | $ | ||||||
Goodwill
Goodwill consisted of the following as of September 30, 2026 and December 31, 2025:
| Balance as of December 31, 2025 | $ | |||
| Impairment loss | ( | ) | ||
| Foreign currency translation | ( | ) | ||
| Balance as of March 31, 2026 | $ | |||
| Impairment loss | ( | ) | ||
| Foreign currency translation | ( | ) | ||
| Balance as of June 30, 2026 | $ | |||
| Foreign currency translation | ( | ) | ||
| Balance as of September 30, 2026 | $ |
11
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 4 — Balance Sheet Details (cont.)
Impairments for three and nine months ended September 30, 2026 and 2025
During the three and nine months ended September 30, 2026 and 2025, the Company’s stock price and market capitalization declined, and the Company determined that this was an indicator of a potential impairment of its goodwill. Accordingly, as of September 30, 2026 and 2025, the Company performed quantitative analyses to identify and measure the amount of impairment losses to be recognized. The Company did not recognize any goodwill impairment losses for the three months ended September 30, 2026 and 2025, respectively. The Company recognized goodwill impairment losses of approximately $
The fair value of the reporting unit is estimated using a market approach. Beginning in the second quarter of 2024, the Company elected to use a market capitalization reconciliation methodology as its sole valuation technique in estimating the fair value of the reporting unit. Under this approach, the fair value of the reporting unit is determined based on the Company's market capitalization, calculated using the quoted market price of its common stock and outstanding shares, with consideration given to whether adjustments are necessary to reconcile market capitalization to the fair value of the reporting unit.
Accrued Expenses
Accrued expenses consisted of the following as of September 30, 2026 and December 31, 2025:
| September 30, 2026 | December 31, 2025 | |||||||
| Accrued compensation | $ | $ | ||||||
| Accrued professional fees | ||||||||
| Accrued franchise taxes | ||||||||
| Other accrued expenses | ||||||||
| Total | $ | $ | ||||||
Note 5 — Significant Agreements
Immunovia AB
On September 17, 2025, Proteomedix entered into a license agreement with Immunovia AB, pursuant to which Immunovia obtained exclusive rights to certain intellectual property and proprietary biological materials related to the PancreaSure™ test. In exchange for these rights, Immunovia paid Proteomedix a non-refundable upfront license fee of $
The agreement also provides that Proteomedix will supply biological materials to Immunovia upon receipt of a purchase order. The Company accounts for each sale of biological materials as a separate performance obligation and recognizes the related revenue at a point in time when control of the materials transfers to Immunovia. During the three and nine months ended September 30, 2026, the Company recognized $
12
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 6 — Notes Payable
Insurance Financing
During the nine months ended September 30, 2026, the Company obtained financing for certain Director & Officer liability insurance policy premiums. The agreement assigns the lender a first priority lien on and security interest in the financed policies and any additional premium required in the financed policies.
The total premiums, taxes and fees financed are approximately $
Note 7 — Subscription Agreement
On December 18, 2023, the Company entered into a subscription agreement (the “Subscription Agreement”) with the PMX Investor, who became a stockholder of Onconetix at the closing of the PMX Transaction, for the sale of
As of September 30, 2026 and December 31, 2025, the fair value of the related party subscription agreement liability was $
13
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 8 — Warrant and derivative liabilities
Contingent warrant liabilities
The following table summarizes the activity for the contingent warrant liabilities, using unobservable Level 3 inputs, for the three and nine months ended September 30, 2026:
| Contingent Warrant Liability | ||||
| Balance at December 31, 2025 | ||||
| Change in fair value | ( | ) | ||
| Balance at March 31, 2026 | $ | |||
| Change in fair value | ||||
| Balance at June 30, 2026 | $ | |||
| Change in fair value | ||||
| Balance at September 30, 2026 | $ | |||
Series D derivative liabilities and warrant liabilities
On September 22, 2025, the Company completed a private placement transaction with institutional investors, resulting in the issuance of Series D convertible preferred stock and accompanying warrants to purchase shares of common stock. In connection with the Series D PIPE Financing, the Company recorded warrant liabilities related to the Series D Warrants and derivative liabilities associated with certain embedded features in the Series D Preferred Stock. These instruments were classified as liabilities and measured at fair value in accordance with ASC 815 due to their settlement provisions and other contractual terms. Following the execution of a Limited Waiver Agreement to the Series D Warrants in December 2025, the warrants qualified for equity classification and were reclassified from liabilities to permanent equity and are no longer subject to recurring fair value measurement. Refer to Note 9 for further details on the private placement transaction.
The Company measured its bifurcated embedded derivative liabilities as of September 30, 2026, and December 31, 2025 at fair value on a recurring basis using level 3 inputs. These financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment and estimation. The derivative liabilities and warrant liabilities were both measured using Monte Carlo valuation models. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates.
As of December 11, 2025, the Company had entered a letter of intent with Realbotix (“LOI”), which contemplates a change of control transaction. A closing condition of the LOI is that no convertible securities of the Company will be outstanding prior to, or upon, closing (subject to approval of the preferred shareholders) which creates two distinct timing scenarios for the settlement of the preferred securities: prior to, or at closing, pursuant to the terms of the LOI or after closing in the event the transaction proposed by the LOI is not completed. Given the disparate timing conditions, the valuation included two scenarios in the Monte Carlo valuation analysis as of September 30, 2026 and December 31, 2025: Closing and No Closing. The Closing scenario includes settlement logic for the preferred securities based on the profit-maximizing outcome of the preferred shareholder at the hypothetical closing date. The No Closing scenario models the embedded derivatives as if there was no forced conversion event (similar to valuation analyses of the embedded derivatives as of their original issuance and September 30, 2025).
The table below shows the inputs used to determine the fair value of the Series D derivative liabilities:
| As of | ||||||||||||||||
| September 30, | September 30, | December 31, | December 31, | |||||||||||||
| 2026 | 2026 | 2025 | 2025 | |||||||||||||
| Closing Scenario | Non-closing Scenario | Closing Scenario | Non-closing Scenario | |||||||||||||
| Expected term (years) | ||||||||||||||||
| Expected volatility | % | % | % | % | ||||||||||||
| Expected dividend yield | % | % | % | % | ||||||||||||
| Risk-free interest rate | % | % | % | % | ||||||||||||
| Probability | % | % | % | % | ||||||||||||
The Limited Waiver Agreement executed on December 23, 2025 resulted in reclassification of the warrants to equity, the warrant liability was remeasured using inputs as of December 23, 2025, and no subsequent liability remeasurement was required through December 31, 2025.
14
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 8 — Warrant and derivative liabilities (cont.)
The following table presents information about the Company’s Series D derivative liabilities that are measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
| Valuation Level | September 30, 2026 | December 31, 2025 | ||||||||
| Series D Derivative liabilities | Level 3 | |||||||||
| $ | $ | |||||||||
The following table sets forth a summary of the change in the fair value of the derivative liabilities that are measured at fair value on a recurring basis for the nine months ended September 30, 2026:
| Series D Derivative Liabilities | ||||
| Balance, as of December 31, 2025 | $ | |||
| Change in fair value | ( | ) | ||
| Balance, as of March 31, 2026 | ||||
| Change in fair value | ||||
| Conversion | ( | ) | ||
| Balance, as of June 30, 2026 | $ | |||
| Change in fair value | ( | ) | ||
| Conversion | ( | ) | ||
| Balance, as of September 30, 2026 | $ | |||
Series E derivative liabilities and warrant liabilities
On October 1, 2025, the Company completed a private placement transaction with institutional investors, resulting in the issuance of Series E convertible preferred stock and accompanying warrants to purchase shares of common stock. In connection with the Series E PIPE financing, the Company recorded warrant liabilities related to the Series E Warrants and derivative liabilities associated with certain embedded features in the Series E Preferred Stock. These instruments were classified as liabilities and measured at fair value in accordance with ASC 815 due to their settlement provisions and other contractual terms. Following the execution of a Limited Waiver Agreement to the Series E Warrants in December 2025, the warrants qualified for equity classification and were reclassified from liabilities to permanent equity and are no longer subject to recurring fair value measurement. Refer to Note 9 for further detail on the private placement transaction.
The Company measures its bifurcated embedded derivative liability as of December 31, 2025 and issuance, at fair value on a recurring basis using level 3 inputs. As all remaining shares of Series E Preferred Stock were converted during the six months ended June 30, 2026, no related derivative liability remained outstanding as of September 30, 2026. Accordingly, no fair value measurement was required at that date. These financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. The derivative liability and warrant liability were both measured using Monte Carlo valuation models. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates.
As of December 11, 2025, the Company had entered a letter of intent with Realbotix (“LOI”), which contemplates a change of control transaction. A closing condition of the LOI is that no convertible securities of the Company will be outstanding prior to, or upon, closing (subject to approval of the preferred shareholders) which creates two distinct timing scenarios for the settlement of the preferred securities: prior to, or at closing, pursuant to the terms of the LOI or after closing in the event the transaction proposed by the LOI is not completed. Given the disparate timing conditions, the valuation included two scenarios in the Monte Carlo valuation analysis as of September 30, 2026 and December 31, 2025: Closing and No Closing. The Closing scenario includes settlement logic for the preferred securities based on the profit-maximizing outcome of the preferred shareholder at the hypothetical closing date. The No Closing scenario models the embedded derivatives as if there was no forced conversion event (similar to valuation analyses of the embedded derivatives as of their original issuance and September 30, 2025).
15
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 8 — Warrant and derivative liabilities (cont.)
The table below shows the inputs used to determine the fair value of the Series E derivative liabilities:
| As of | ||||||||||||||||
| September 30, | September 30, | December 31, | December 31, | |||||||||||||
| 2026 | 2026 | 2025 | 2025 | |||||||||||||
| Closing Scenario | Non-closing Scenario | Closing Scenario | Non-closing Scenario | |||||||||||||
| Expected term (years) | N/A | N/A | ||||||||||||||
| Expected volatility | N/A | N/A | % | % | ||||||||||||
| Expected dividend yield | N/A | N/A | % | % | ||||||||||||
| Risk-free interest rate | N/A | N/A | % | % | ||||||||||||
| Probability | N/A | N/A | % | % | ||||||||||||
The Limited Waiver Agreement executed on December 23, 2025 resulted in reclassification of the warrants to equity, the warrant liability was remeasured using inputs as of December 23, 2025, and no subsequent liability remeasurement was required through December 31, 2025.
The following table presents information about the Company’s derivative liabilities that are measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
| Valuation Level | September 30, 2026 | December 31, 2025 | ||||||||
| Series E Derivative liabilities | Level 3 | — | ||||||||
| $ | — | $ | ||||||||
The following table sets forth a summary of the change in the fair value of the derivative liabilities that are measured at fair value on a recurring basis for the nine months ended September 30, 2026:
| Series E - Derivative Liabilities | ||||
| Balance, as of December 31, 2025 | $ | |||
| Change in fair value | ( | ) | ||
| Balance, as of March 31, 2026 | ||||
| Conversions | ( | ) | ||
| Balance, as of June 30, 2026 | $ | — | ||
| Change in fair value | — | |||
| Balance, as of September 30, 2026 | $ | — | ||
16
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 8 — Warrant and derivative liabilities (cont.)
Series F derivative liabilities
On July 28, 2026, the Company completed a private placement with an accredited investor (the “Series F PIPE Financing”). In that placement it issued
The Company measured its bifurcated embedded derivative liability related to the Series F Preferred Stock as of September 30, 2026 and July 28, 2026, at fair value on a recurring basis using level 3 inputs. These financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. The derivative liability was measured using a Monte Carlo valuation model. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates.
As of December 11, 2025, the Company had entered a letter of intent with Realbotix (“LOI”), which contemplates a change of control transaction. A closing condition of the LOI is that no convertible securities of the Company will be outstanding prior to, or upon, closing (subject to approval of the preferred shareholders) which creates two distinct timing scenarios for the settlement of the preferred securities: prior to, or at closing, pursuant to the terms of the LOI or after closing in the event the transaction proposed by the LOI is not completed. Given the disparate timing conditions, the valuation included two scenarios in the Monte Carlo valuation analysis as of September 30, 2026 and July 28, 2026: Closing and No Closing. The Closing scenario includes settlement logic for the preferred securities based on the profit-maximizing outcome of the preferred shareholder at the hypothetical closing date. The No Closing scenario models the embedded derivatives as if there was no forced conversion event.
The table below shows the inputs used to determine the fair value of the Series F derivative liabilities:
| As of | ||||||||||||||||
| September 30, | September 30, | July 28, | July 28, | |||||||||||||
| 2026 | 2026 | 2026 | 2026 | |||||||||||||
| Closing Scenario | Non-closing Scenario | Closing Scenario | Non-closing Scenario | |||||||||||||
| Expected term (years) | ||||||||||||||||
| Expected volatility | % | % | % | % | ||||||||||||
| Expected dividend yield | % | % | % | % | ||||||||||||
| Risk-free interest rate | % | % | % | % | ||||||||||||
| Probability | % | % | % | % | ||||||||||||
17
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 8 — Warrant and derivative liabilities (cont.)
The following table presents information about the Company’s Series F derivative liabilities that are measured at fair value on a recurring basis as of September 30, 2026 and July 28, 2026, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
| Valuation Level | September 30, 2026 | July 28, 2026 | ||||||||
| Series F derivative liabilities | Level 3 | |||||||||
| $ | $ | |||||||||
The following table sets forth a summary of the change in the fair value of the derivative liabilities that are measured at fair value on a recurring basis for the three months ended September 30, 2026:
| Series F Derivative Liabilities | ||||
| Balance, as of June 30, 2026 | $ | — | ||
| Fair value recognized upon issuance | ||||
| Conversions | ( | ) | ||
| Change in fair value | ( | ) | ||
| Balance, as of September 30, 2026 | $ | |||
Note 9 — Convertible Preferred Stock and Stockholders’ Equity
Authorized Capital
As of September 30, 2026 and December 31, 2025, the Company is authorized to issue
At September 30, 2026 and December 31, 2025, the Company had designated
18
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 9 — Convertible Preferred Stock and Stockholders’ Equity (cont.)
Preferred Stock
Series Seed Convertible Preferred Stock
The Company has
Series A Convertible Preferred Stock
On September 29, 2023, the Company filed a Certificate of Designations of Rights and Preferences of Series A Preferred Stock of the Company (the “Series A Certificate of Designations”) with the State of Delaware to designate and authorize the issuance of up to
On October 3, 2023, the Company issued
On September 24, 2024, Veru converted all
Series B Convertible Preferred Stock
In connection with the PMX acquisition on December 15, 2023, the Company issued
Series C Convertible Preferred Stock
On October 1, 2024, the Board of Directors authorized the Company to create a series of
On July 16, 2025, the Company exercised its voluntary Series C Preferred Stock adjustment right to lower the conversion price of the Series C Preferred Stock to $
19
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 9 — Convertible Preferred Stock and Stockholders’ Equity (cont.)
Series D Preferred Stock
On September 22, 2025, the Company entered into a securities purchase agreement (the “Series D Securities Purchase Agreement” and the financing contemplated therein, the “Series D PIPE Financing”) with eleven institutional investors, and sold or exchanged debt, to such investors (collectively, the “Series D PIPE Investors”) an aggregate of
The Series D Preferred Stock was determined to be more akin to an equity-like host than a debt-like host and was classified as permanent equity as it was not redeemable in any manner that would require classification outside of permanent equity pursuant to ASC 480-10-S99. The Series D Preferred Stock was recorded on the accompanying consolidated balance sheet at its par value. Certain embedded share-settled redemption features within the Series D Preferred Stock were bifurcated and accounted for separately as a derivative liability.
The Series D Warrants and certain embedded share-settled redemption features of the Series D Preferred Stock issued were determined to be liability-classified instruments pursuant to ASC 480 and ASC 815. The embedded features of the Series D Preferred Stock were bifurcated and accounted for separately as derivative liabilities. The Company measured the warrant liabilities and bifurcated derivative liabilities at fair value on a recurring basis using Level 3 inputs as of September 22, 2025 (the issuance date), December 23, 2025 (amended warrants date), December 31, 2025 (derivative liabilities fair value date) and September 30, 2026, respectively. See Note 8 for further information regarding the valuation methodology and assumptions used in determining the fair value of the warrant and derivative liabilities.
The Series D Preferred Stock has no voting rights. The Series D Preferred Stock are convertible into common stock at the election of the holders of the Series D Preferred Stock at any time at an initial conversion price of $
The Series D Preferred Stock is not redeemable by the holder except in the event of 1) a liquidation, dissolution, or winding up, or 2) the Series D Preferred Stock is redeemable for common stock of the Company upon the occurrence of a change in control. Holders of the Series D Preferred Stock shall be entitled to receive dividends as authorized and declared by the Company’s Board of Directors, payable in cash, securities, or in other assets as determined by the Company’s Board of Directors.
In the event of the Company’s liquidation, dissolution, or winding up, holders of the Series D Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, an amount equal to the stated value of the Series D Preferred Stock, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages owed before any distribution or payment shall be made to the holders of any junior securities.
During the nine months ended September 30, 2026, holders of Series D Preferred Stock converted
Series E Preferred Stock
On October 1, 2025, Onconetix entered into, and sold to institutional investor(s) (collectively, the “PIPE Investors”), pursuant to a securities purchase agreement (the “Securities Purchase Agreement”) an aggregate of
20
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 9 — Convertible Preferred Stock and Stockholders’ Equity (cont.)
The Series E Preferred Stock was determined to be more akin to an equity-like host than a debt-like host and was classified as permanent equity as it was not redeemable in any manner that would require classification outside of permanent equity pursuant to ASC 480-10-S99. The Series E Preferred Stock was recorded on the accompanying consolidated balance sheet at its par value. Certain embedded share-settled redemption features within the Series E Preferred Stock were bifurcated and accounted for separately as a derivative liability.
The Series E Warrants and certain embedded share-settled redemption features of the Series E Preferred Stock issued were determined to be liability-classified instruments pursuant to ASC 480 and ASC 815. The embedded features of the Series E Preferred Stock were bifurcated and accounted for separately as derivative liabilities. The Company measured the warrant liabilities and bifurcated derivative liabilities at fair value on a recurring basis using Level 3 inputs as of October 1, 2025 (the issuance date), December 23, 2025 (amended warrants date) and December 31, 2025 (derivative liabilities fair value date). See Note 8 for further information regarding the valuation methodology and assumptions used in determining the fair value of the warrant and derivative liabilities.
The Series E Preferred Stock has no voting rights. The Series E Preferred Stock are convertible into common stock at the election of the holders of the Series E Preferred Stock at any time at an initial conversion price of $
The Series E Preferred Stock is not redeemable by the holder except in the event of 1) a liquidation, dissolution, or winding up, or 2) the Series E Preferred Stock is redeemable for common stock of the Company upon the occurrence of a change in control. Holders of the Series E Preferred Stock shall be entitled to receive dividends as authorized and declared by the Company’s Board of Directors, payable in cash, securities, or in other assets as determined by the Company’s Board of Directors.
In the event of the Company’s liquidation, dissolution, or winding up, holders of the Series E Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, an amount equal to the stated value of the Series E Preferred Stock, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages owed before any distribution or payment shall be made to the holders of any junior securities.
As of December 31, 2025, all
Series F Preferred Stock
On July 28, 2026, the Company entered into a securities purchase agreement (the “Series F Securities Purchase Agreement” and the financing contemplated therein, the “Series F PIPE Financing”) with an accredited investor (the “Series F PIPE Investor”). Under that agreement, the Company issued
Under the July 2026 ELOC Purchase Agreement, the Company has the right, but not the obligation, to sell up to $
21
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 9 — Convertible Preferred Stock and Stockholders’ Equity (cont.)
The Series F Preferred Stock was determined to be more akin to an equity-like host than a debt-like host. It is classified in temporary equity under ASC 480-10-S99-3A. If the Company does not have sufficient authorized shares of common stock to settle a conversion, it must redeem in cash the portion it cannot settle in shares. Increasing the number of authorized shares requires stockholder approval, so this event is not solely within the Company’s control. The Series F Preferred Stock is not currently redeemable, and it is not probable that it will become redeemable. Accordingly, its carrying amount has not been adjusted to its redemption amount. The Company evaluated whether it is probable that the Series F Preferred Stock will become redeemable. The redemption feature is triggered only if the Company has insufficient authorized shares to settle a conversion. Management concluded that redemption was not probable at September 30, 2026 because i) the Company has the ability to and intends to seek stockholder approval to increase authorized shares under its certificate of incorporation, as amended, and ii) the closing condition under the Share Exchange Agreement requires that no convertible securities be outstanding. The initial measurement of the Series F Preferred Stock is described under “ELOC Commitment Fee.”
Certain embedded features of the Series F Preferred Stock were determined not to be indexed to the Company’s own stock. These are the variable-price and alternate conversion features, the change of control rights and the exchange right. They were bifurcated and accounted for separately as a single compound derivative liability pursuant to ASC 815. The Company measured the derivative liability at fair value on a recurring basis using Level 3 inputs as of July 28, 2026 (the issuance date) and September 30, 2026. See Note 8 for further information on the valuation methodology and assumptions used to determine the fair value of the derivative liability.
Terms of the Series F Preferred Stock
The Series F Preferred Stock has no voting rights, except as required by law. To the extent holders are entitled to vote together with holders of Common Stock, the Series F Preferred Stock votes on an as-converted basis, subject to beneficial ownership limitations.
Holders may convert the Series F Preferred Stock into Common Stock at any time at an initial conversion price of $
The Series F Preferred Stock is not redeemable at the option of the holder, except in two cases. First, the Company must pay cash in lieu of shares upon conversion if it does not have sufficient authorized shares of Common Stock. Second, upon a change of control, holders may require an exchange of their shares for rights or, at the Company’s election, cash. The Company may redeem the Series F Preferred Stock at any time in cash, subject to certain conditions. The redemption price is
In the event of the Company’s liquidation, dissolution or winding up, holders of the Series F Preferred Stock are entitled to receive an amount per share equal to the greater of (i)
During the three and nine months ended September 30, 2026, holders of Series F Preferred Stock converted
22
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 9 — Convertible Preferred Stock and Stockholders’ Equity (cont.)
July 2026 ELOC Commitment Fee
The July 2026 ELOC Purchase Agreement defines the commitment consideration as the Series F Preferred Stock, and those shares were fully earned at closing regardless of whether the Company ever sells shares under the ELOC and regardless of any termination. The Company therefore measured the transaction at the fair value of the Series F Preferred Stock issued, which was $
The fair value of the Series F Preferred Stock at issuance was a nonrecurring fair value measurement classified within Level 3 of the fair value hierarchy because it relies on significant unobservable inputs. Management estimated the fair value with the assistance of an independent valuation specialist using a Monte Carlo simulation. The simulation weighted a scenario in which the proposed Realbotix transaction closes and the Series F Preferred Stock is converted or settled at closing, and a scenario in which the transaction does not close and the Series F Preferred Stock remains outstanding over the Company’s expected cash runway. The significant inputs were a
The Company evaluated whether the commitment fee should instead be capitalized as an asset, either as a deferred offering cost to be charged against proceeds of future sales under the ELOC or as a cost of obtaining a financing commitment to be amortized over the term of the agreement. The Company concluded that capitalization was not appropriate because the fee does not represent a recoverable asset, for the following reasons:
| ● | The Company cannot sell any shares under the ELOC until a resale registration statement is declared effective; | |
| ● | Sales are limited by a | |
| ● | The Company may terminate the ELOC at any time, and the investor may terminate it upon a fundamental transaction, including the proposed Realbotix transaction; | |
| ● | The fee was fully earned and non-refundable at closing, regardless of whether the Company sells any shares under the ELOC; and | |
| ● | The fee significantly exceeds the amount the Company reasonably expects to raise under the ELOC, and the Company does not believe it is probable that future proceeds will recover it. |
The Company also considered whether the commitment fee should be recorded as a cost of issuing equity and charged against additional paid-in capital, either against the proceeds of the Series F Preferred Stock or against the proceeds of future sales of common stock under the ELOC. The Company concluded that neither treatment was appropriate. The fee is not an incremental cost of issuing the Series F Preferred Stock. The Series F Preferred Stock was itself the consideration delivered to the investor for the ELOC commitment, and the cash received was a small fraction of the $
In addition, the Company’s right to sell shares under the ELOC is accounted for as a derivative and had a de minimis fair value at inception and at September 30, 2026, because shares are sold at a price that resets to market at each sale. The Company therefore did not recognize an asset for the commitment, and the cost of obtaining the commitment was expensed as incurred. The commitment fee was settled through the issuance of Series F Preferred Stock and was a noncash expense.
Issuance costs
In connection with the Series F PIPE Financing, the Company incurred direct and incremental issuance costs of $
23
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 9 — Convertible Preferred Stock and Stockholders’ Equity (cont.)
October 2024 ELOC
On October 2, 2024, the Company entered into a Common Stock Equity Line of Credit Purchase Agreement (the “ELOC Purchase Agreement”) with an institutional investor, whereby the Company may sell up to $
On October 11, 2024, holders of a majority of the voting power of the Company’s outstanding Common Stock approved by written consent, in accordance with Nasdaq Listing Rule 5635(d), the issuance of all shares of Common Stock under the ELOC Purchase Agreement, including shares in excess of
During the three months ended September 30, 2026 and 2025, the Company received proceeds of $
July 2026 ELOC
On July 28, 2026, the Company entered into a Common Stock Purchase Agreement (the “July 2026 ELOC Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), concurrently with the Series F PIPE Financing. Under the agreement, the Company has the right, but not the obligation, to sell to Seven Knots, from time to time at its sole discretion, up to the lesser of (i) $
In consideration for Seven Knots’ commitment, the Company issued
During the three and nine months ended September 30, 2026, the Company received proceeds of $
Common Stock
As of September 30, 2026 and December 31, 2025 there were
Treasury Stock
On November 10, 2022, the Board approved a stock repurchase program (the “Repurchase Program”) to allow the Company to repurchase up to
There were no repurchases of common stock during the nine months ended September 30, 2026 and 2025.
On November 13, 2024, the Board terminated the Repurchase Program.
24
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 9 — Convertible Preferred Stock and Stockholders’ Equity (cont.)
Warrants
The following summarizes the Company’s outstanding warrants, excluding contingent warrants issuable upon exercise of the outstanding warrants as of September 30, 2026:
| Number of Shares | WA Average Exercise Price | WA Remaining Contractual Life (in years) | ||||||||||
| Outstanding as of December 31, 2025 | ||||||||||||
| Granted | — | — | — | |||||||||
| Exercised | ( | ) | — | — | ||||||||
| Cancelled | — | — | — | |||||||||
| Outstanding as of March 31, 2026 | ||||||||||||
| Granted | — | — | — | |||||||||
| Exercised | — | — | — | |||||||||
| Cancelled | — | — | — | |||||||||
| Outstanding as of June 30, 2026 | ||||||||||||
| Granted | — | — | — | |||||||||
| Exercised | — | — | — | |||||||||
| Cancelled | ( | ) | — | — | ||||||||
| Outstanding as of September 30, 2026 | ||||||||||||
| Warrants vested and exercisable as of September 30, 2026 | ||||||||||||
As of September 30, 2026, the Company had outstanding warrants, which are exercisable into
On May 21, 2026, the Company effected a
As a result of this price-reset feature, the anti-dilution adjustment increased the number of shares issuable upon exercise of the affected warrants after giving effect to the reverse stock split, rather than decreasing solely in proportion to the reverse stock split ratio. Based on the adjusted exercise price, the Company determined that an aggregate of
Contingent Warrant Liabilities
As of September 30, 2026, the fair value of contingent warrant liabilities includes the Series C PIPE warrants of $
As of December 31, 2025, the fair value of contingent warrant liabilities includes the Series C Warrants of $
25
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 9 — Convertible Preferred Stock and Stockholders’ Equity (cont.)
Onconetix Equity Incentive Plans
The Company’s 2019 Equity Incentive Plan (the “2019 Plan”) was adopted by its board of directors and by its stockholders on July 1, 2019. On February 23, 2022 the Company’s board of directors adopted the Company’s 2022 Equity Incentive Plan (the “2022 Plan”), which is the successor and continuation of the Company’s 2019 Plan. Under the 2022 Plan, the Company may grant stock options, restricted stock, restricted stock units, stock appreciation rights, and other forms of awards to employees, directors, and consultants of the Company. In May 2023, the number of shares of common stock reserved for issuance under the 2022 Plan was increased to
Stock Options
There were no stock options granted during the three and nine months ended September 30, 2026 and 2025.
The aggregate fair value of stock options that vested during the three and nine months ended September 30, 2026, was approximately $
Restricted Stock
The following summarizes activity related to the Company’s restricted stock awards granted under the 2022 Plan for the nine months ended September 30, 2026:
| Weighted | ||||||||
| Average | ||||||||
| Number of | Grant Date | |||||||
| Shares | Fair Value | |||||||
| Nonvested as of December 31, 2025 | $ | |||||||
| Granted | — | — | ||||||
| Vested | — | — | ||||||
| Forfeited | ( | ) | ||||||
| Nonvested as of March 31, 2026 | $ | |||||||
| Granted | — | — | ||||||
| Vested | — | — | ||||||
| Forfeited | ( | ) | ||||||
| Nonvested as of June 30, 2026 | — | $ | — | |||||
| Granted | — | — | ||||||
| Vested | — | — | ||||||
| Forfeited | — | — | ||||||
| Nonvested as of September 30, 2026 | — | $ | — | |||||
Proteomedix Stock Option Plan
Proteomedix sponsors a stock option plan (the “PMX Option Plan”) which provides common stock option grants to be granted to certain employees and consultants, as was determined by the board of directors of Proteomedix. In connection with the PMX Transaction, the Company assumed the PMX Option Plan.
Generally, options issued under the PMX Option Plan have a term of not more than
26
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 9 — Convertible Preferred Stock and Stockholders’ Equity (cont.)
There was no activity under the PMX Option Plan for the nine months ended September 30, 2026 and 2025. As of September 30, 2026 and December 31, 2025, there were no outstanding stock options under the PMX Option Plan.
Stock-Based Compensation
Stock-based compensation expense related to stock options and restricted stock, for the three and nine months ended September 30, 2026 and 2025 was as follows:
| For the Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Selling, general and administrative | $ | — | $ | |||||
| Research and development | — | — | ||||||
| Total | $ | — | $ | |||||
| For the Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Selling, general and administrative | $ | $ | ||||||
| Research and development | — | — | ||||||
| Total | $ | $ | ||||||
Note 10 — Commitments and Contingencies
Office Lease
Proteomedix leases office and lab space in Zurich, Switzerland. In May 2025, Proteomedix entered into a lease amendment to reduce its leased premises. Effective June 30, 2025, the Company terminated the April 2024 lease amendment, which included office space and laboratory space. Additionally, a partial termination of a prior lease amendment further reduced the office space.
This lease expired on
Litigation
From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. As of September 30, 2026, the Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims.
Indemnification
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been required to defend any action related to its indemnification obligations. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not estimable at this time.
27
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 11 — Related Party Transactions
On June 17, 2025, the Company entered into a separate consulting agreement with a firm affiliated with Dr. Meier. The agreement provides for the payment of certain success fees and reimbursement of related expenses. Under its terms, Dr. Meier is entitled to earn up to
Note 12 — Net Loss Per Share
Basic net loss per share is computed by dividing the net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. The weighted average number of shares of common stock outstanding includes pre-funded warrants because their exercise requires only nominal consideration for delivery of shares; it does not include any potentially dilutive securities or any unvested restricted shares of common stock. Certain restricted shares, although classified as issued and outstanding at September 30, 2026, are considered contingently returnable until the restrictions lapse and will not be included in the basic net loss per share calculation until the shares are vested. Unvested shares of the Company’s restricted stock do not contain non-forfeitable rights to dividends and dividend equivalents.
The two-class method is used to determine earnings per share based on participation rights of participating securities in any undistributed earnings. Each share of preferred stock that includes rights to participate in distributed earnings is considered a participating security and the Company uses the two-class method to calculate net income available to the Company’s common stockholders per common share — basic and diluted.
The following securities were excluded from the computation of diluted shares outstanding due to the losses incurred in the periods presented, as they would have had an anti-dilutive impact on the Company’s net loss:
| As of September 30, | ||||||||
| 2026 | 2025 | |||||||
| Options to purchase shares of common stock | — | |||||||
| Warrants | ||||||||
| Unvested shares of restricted stock | — | |||||||
| Common stock issuable upon conversion of Series C Redeemable Preferred Stock | ||||||||
| Common stock issuable upon conversion of Series D Redeemable Preferred Stock | ||||||||
| Common stock issuable upon conversion of Series F Redeemable Preferred Stock | — | |||||||
| Total | ||||||||
Note 13 — Segment Information
The Company conducts its business activities and reports financial results as one business segment. The presentation of financial results as one reportable segment is consistent with the way the Company operates its business and is consistent with the manner in which the Chief Operating Decision Maker (“CODM”) evaluates performance and makes resource and operating decisions for the business.
28
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 13 — Segment Information (cont.)
The tables below present segment information reconciled to total Company net loss, with segment net loss including gross profit less direct research and development expenses and direct selling, general and administrative expenses, and other income (expenses) to the extent specifically identified by segment:
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | $ | $ | $ | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general, and administrative | ||||||||||||||||
| Research and development | ( | ) | ( | ) | ||||||||||||
| Impairment of goodwill | — | — | ||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other (expense) income | ||||||||||||||||
| Loss on extinguishment of note payable | — | ( | ) | — | ( | ) | ||||||||||
| Loss on issuance of preferred stock and warrants | — | ( | ) | — | ( | ) | ||||||||||
| Loss on extinguishment of preferred stock | — | ( | ) | — | ( | ) | ||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Change in fair value of subscription agreement liability – related party | — | — | — | |||||||||||||
| Change in fair value of contingent warrant liabilities | ( | ) | ( | ) | ( | ) | ||||||||||
| Change in fair value of Series D Derivative Liability | ( | ) | ( | ) | ||||||||||||
| Change in fair value of Series E Derivative Liability | — | — | — | |||||||||||||
| Change in fair value of Series F Derivative Liability | — | — | ||||||||||||||
| Change in fair value of Series D Warrant Liability | — | — | ||||||||||||||
| ELOC commitment fee | ( | ) | — | ( | ) | — | ||||||||||
| Gain on forgiveness of accounts payable | — | — | — | |||||||||||||
| Other income (loss) | ( | ) | ( | ) | ||||||||||||
| Total other income (loss) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
29
ONCONETIX, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 2026
(Unaudited)
Note 13 — Segment Information (cont.)
Geographic Information
The distribution of revenue by geographical area was as follows:
| Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| United States | $ | — | $ | — | ||||
| United Kingdom | — | |||||||
| Switzerland | ||||||||
| Total | $ | $ | ||||||
| Nine months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| United States | $ | — | $ | — | ||||
| United Kingdom | ||||||||
| Switzerland | ||||||||
| Total | $ | $ | ||||||
Note 14 — Subsequent Events
Advance under Grid Promissory Note
On October 22, 2026, the Company made an additional advance of $
Amendment to Share Exchange Agreement
On November 4, 2026, the Company, Realbotix Corp., Simulacra Corporation, and Realbotix entered into the First Amendment to the Share Exchange Agreement (the “First Amendment”). Unless otherwise defined herein, the capitalized terms used below are defined in the Share Exchange Agreement.
Pursuant to the First Amendment, the Parties agreed that (i) if the Net Cash is less than $
November 2026 Reverse Stock Split
On November 6, 2026, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-ten
Conversions of Series D Preferred Stock
Subsequent to September 30, 2026, the holder of the Series D Preferred Stock converted
Sales under October 2024 ELOC
Subsequent to September 30, 2026, the Company sold
30
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes to those statements included elsewhere in this Report and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, on March 13, 2026. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors. See “Cautionary Note Regarding Forward-Looking Statements.”
Overview
We are a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology. Through our acquisition of Proteomedix, which closed on December 15, 2023, we own Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation (“IVDR”), which we anticipate will be marketed in the U.S. as a lab developed test through our license agreement with LabCorp.
Since our inception in October 2018 until April 2023, when we acquired ENTADFI, we devoted substantially all of our resources to performing research and development, undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, hiring personnel, acquiring and developing our technology and now halted vaccine candidates, organizing and staffing our company, performing business planning, establishing our intellectual property portfolio and raising capital to support and expand such activities.
ENTADFI is an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of BPH, a disorder of the prostate. However, in light of (i) the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii) the Company’s cash runway and indebtedness, the Company abandoned commercialization of ENTADFI and no longer holds remaining inventory of the product as of December 31, 2025. In addition, as part of cost reduction efforts and in connection with our initial pause in commercializing ENTADFI, we terminated three employees involved with the ENTADFI program, effective April 30, 2024, with such individuals to continue assisting the Company on an as-needed, consulting basis. Based on the circumstances surrounding ENTADFI, at June 30, 2024, the ENTADFI assets were fully impaired.
Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (“PSA”) test. The PSA test is a well-established prostate specific marker that measures the concentration of PSA molecules in a blood sample. A high level of PSA can be a sign of prostate cancer. However, PSA levels can also be elevated for many other reasons including infections, prostate stimulation, vigorous exercise or even certain medications. PSA results can be confusing for many patients and even physicians. It is estimated over 50% of biopsies with elevated PSA are negative or clinically insignificant resulting in an overdiagnosis and overtreatment that impacts the physician’s routine, our healthcare system, and the quality of patients’ lives. Approximately 10% of all men have elevated PSA levels, commonly referred to as the diagnostic “grey zone”, of which only 20 - 40% present clinically with cancer. Proclarix is intended for use in diagnosing these patients where it is difficult to decide if a biopsy is necessary to verify a potential clinically significant cancer diagnosis. Proclarix helps doctors and patients with unclear PSA test results through the use of our proprietary Proclarix Risk Score which delivers clear and immediate diagnostic support for further treatment decisions. No additional intervention is required, and results are available quickly. Local diagnostic laboratories can integrate this multiparametric test into their current workflow because Proclarix assays use the enzyme-linked immunosorbent assay (ELISA) standard, which most diagnostic laboratories are already equipped to process.
There were two new peer-reviewed scientific publications published in the first quarter of 2026 on the clinical utility of Proclarix. The first paper, by Schiess et al., has been accepted for publication in BMC Cancer, an open-access oncology research journal. The study evaluated Proclarix in a cohort of 371 men and ruled out clinically insignificant or absent prostate cancer while maintaining a low risk of missing csPCa. Proclarix was subsequently shown to significantly reduce overdiagnosis and unnecessary biopsies, outperforming both %fPSA and the ERSPC risk calculator. The second paper, by Athanasiou et al., has been published in the journal Cancers (2026, 18, 1348-62). In a cohort of 132 men under active surveillance, the study demonstrated the prognostic value of Proclarix® and its risk score in predicting the transition of patients from active surveillance to active treatment.
Proclarix is CE-marked and for sale in Europe. In the United Kingdom, Proclarix is now offered by a patient organization as an additional option within a screening initiative for early identification of prostate cancer.
31
We continue our sales efforts and expect growing revenues from sales of Proclarix in 2026 and beyond. We anticipate these sales to offset some expenses relating to commercial scale up and development, we expect our expenses also to increase in connection with our ongoing activities, as we:
| ● | commercialize Proclarix; |
| ● | hire additional personnel; |
| ● | operate as a public company; |
| ● | obtain, maintain, expand, and protect our intellectual property portfolio; and |
| ● | perform product validation studies in connection with a license agreement. |
In June 2026, Proteomedix initiated a PRIME study, a multi-center clinical validation study conducted in collaboration with Labcorp to evaluate Proclarix in the U.S. market and across various ethnicities. The first participants have been enrolled and the study is designed to ultimately include up to 500 men.
We rely and will continue to rely on third parties for the manufacturing of Proclarix. We have no internal manufacturing capabilities, and we will continue to rely on third parties, of which the main suppliers are single-source suppliers, for commercial product.
We do not have any products approved for sale, aside from Proclarix. We have abandoned commercialization of ENTADFI and have destroyed our inventory of the product.
To date, we have financed our operations primarily with proceeds from our sale of preferred securities to seed investors, the initial public offering (“IPO”), and subsequent offerings of debt and equity securities. We will continue to require significant additional capital to commercialize Proclarix, and to fund operations for the foreseeable future. Accordingly, until such time as we can generate significant revenue, if ever, we expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and to rely on third-party resources for marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches, to support our operations.
Some recent key developments affecting our business include the following:
2026 Annual Meeting of Stockholders
On November 10, 2026, the Company held its annual meeting of stockholders (the “Annual Meeting”) whereby its stockholders approved, among other things, i) the re-election of Josh Epstein as a Class II director on the Board for a three-year term, ii) the issuance of certain shares of Common Stock upon the conversion of the Series F Preferred Stock in accordance with the listing rules of Nasdaq, iii) an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of all of the outstanding shares of Common Stock at a ratio in the range of 1-for-2 to 1-for-15 at any time prior to the one-year anniversary date of the Annual Meeting, with such ratio to be determined by the Board or without further approval or authorization of the Company’s stockholders.
November 2026 Reverse Stock Split
On November 6, 2026, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-ten (1:10). The Company accounted for the reverse stock split on a retrospective basis pursuant to ASC 260, Earnings Per Share. All issued and outstanding common stock, common stock warrants, and share-based awards’ exercise prices and per share data have been adjusted in these consolidated financial statements, on a retrospective basis, to reflect the reverse stock split for all periods presented. The number of authorized shares and par value of the preferred stock and common stock were not adjusted because of the reverse stock split.
32
Grid Promissory Note and Guaranty of Payment
On September 11, 2026, the Company entered into a promissory note (the “Grid Promissory Note”) with Realbotix pursuant to which the Company agreed to make available to Realbotix loans in an aggregate principal amount of up to $5.0 million, of which $2.5 million was advanced on September 11, 2026 and $500,000 was advanced on October 22, 2026. As of the date of this Report, $3.0 million of aggregate principal outstanding and $2.0 million of principal available. The proceeds of the Grid Promissory Note may be used by Realbotix for general corporate and working capital purposes. The Grid Promissory Note is an unsecured obligation of Realbotix, matures on September 11, 2027, and does not bear interest prior to the earlier of the closing of the Share Exchange or the termination of the Share Exchange Agreement. If the Share Exchange Agreement is terminated, interest will accrue on the outstanding principal balance at a rate of 12% per annum until the Grid Promissory Note is paid.
Upon the closing of the transactions contemplated by the Share Exchange Agreement, the Grid Promissory Note and all obligations thereunder will automatically be cancelled and discharged, and the Net Cash at Closing under the Share Exchange Agreement will include the aggregate principal amount then outstanding, plus accrued interest outstanding under the Grid Promissory Note.
On November 4, 2026, the parties of the Share Exchange Agreement entered into the First Amendment to the Share Exchange Agreement (the “First Amendment”), which, among other things, provides that Net Cash includes cash, cash equivalents and the unpaid principal balance and accrued interest outstanding under the Grid Promissory Note as of the closing. See “Realbotix Share Exchange Agreement” below for a description of the First Amendment.
Realbotix’s obligations under the Grid Promissory Note are guaranteed by Realbotix Corp. pursuant to a Guaranty of Payment, dated September 11, 2026 (the “Guaranty”).
Series F PIPE Financing
On July 28, 2026, the Company entered into a securities purchase agreement (the “Series F Securities Purchase Agreement”) with an accredited investor (the “Series F PIPE Investor”), pursuant to which the Company agreed to issue and sell to the Series F PIPE Investor an aggregate of 37,812 shares of Series F convertible preferred stock, par value $0.00001 per share (“Series F Preferred Stock”), for an aggregate purchase price of $30,249,600 (the “Series F PIPE Financing”). The Company received net cash proceeds of $134,597 after $115,003 in transaction costs.
Concurrently with entering into the Series F Securities Purchase Agreement, the Company also entered into a registration rights agreement with the Series F PIPE Investor, pursuant to which it agreed to provide the Series F PIPE Investor with certain registration rights related to the shares of Common Stock issuable upon conversion of the Series F Preferred Stock. The Company registered for resale up to 10,000,000 shares of Common Stock issuable upon conversion of a portion of the Series F Preferred Stock pursuant to a registration statement on Form S-1 (File No. 333-298259) which was declared effective by the SEC on September 3, 2026.
July 2026 ELOC Purchase Agreement
On July 28, 2026, the Company entered into a Common Stock Purchase Agreement relating to a committed equity facility (the “July 2026 ELOC Purchase Agreement”) with an accredited investor (“July 2026 ELOC Investor”), pursuant to which, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct the July 2026 ELOC Investor, from time to time and at the Company’s sole discretion, to purchase shares of the Company’s Common Stock having an aggregate purchase price of up to the lesser of (i) $750,000,000 and (ii) 19.99% of the total number of shares of the Company’s Common Stock outstanding immediately prior to the execution of the July 2026 ELOC Purchase Agreement, unless stockholder approval has been obtained or an exception under the applicable Nasdaq listing rules applies. Concurrently with entering into the July 2026 ELOC Purchase Agreement, the Company entered into a Registration Rights Agreement with the July 2026 ELOC Investor (the “July 2026 ELOC Registration Rights Agreement”), pursuant to which the Company agreed to provide the July 2026 ELOC Investor with certain registration rights with respect to the securities issuable under the July 2026 ELOC Purchase Agreement.
In consideration for the July 2026 ELOC Investor’s commitment under the July 2026 ELOC Purchase Agreement, the Company owed a $30,000,000 commitment fee, which the July 2026 ELOC Investor applied toward its purchase of Series F Preferred Stock pursuant to the Series F Securities Purchase Agreement.
33
May 2026 Reverse Stock Split
On May 8, 2026, in reliance of the stockholder approval obtained for the Reverse Stock Split Proposal at the April 2026 Special Meeting held on April 30, 2026, the Board determined to fix a reverse stock split ratio of its Common Stock of 1-to-10 (the “May Reverse Stock Split”). On May 20, 2026, the Company filed an amendment to its COI with the Secretary of State of the State of Delaware to effect the May Reverse Stock Split. The May Reverse Stock Split became effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern Time on May 21, 2026 (the “May Reverse Stock Split Effective Time”). The Company’s Common Stock continues to trade on The Nasdaq Capital Market under the symbol ONCO and has been trading on a split-adjusted basis since the market opened on May 21, 2026. At the May Reverse Stock Split Effective Time, every 10 (ten) shares of the Company’s issued and outstanding Common Stock had converted automatically into one (1) issued and outstanding share of Common Stock, with no corresponding reduction in the number of authorized shares of Common Stock, and without any change in the par value per share.
Result of the Special Meeting of Stockholders of the Company held on April 30, 2026
On April 30, 2026, the Company held a special meeting of stockholders (the “April 2026 Special Meeting”). At the April 2026 Special Meeting, the stockholders of the Company approved the stockholder proposal to grant discretionary authority to Board to further amend COI to effect one or more reverse stock splits of the Common Stock, at a ratio in the range of 1-for-2 to 1-for-10, provided that, (X) the Company shall not effect the aforementioned reverse stock splits that, in the aggregate, exceed 1-for-100, and (Y) any such reverse stock split is completed no later than the one year anniversary date of the April 2026 Special Meeting.
Resignation of Andrew Oakley and Thomas Meier as Directors; Election of Sammy Dorf as Chairman of the Board
Effective on April 20, 2026, Andrew Oakley and Thomas Meier notified the Board of their resignation from the Board. As a result of their resignation from the Board and effective as of the date mentioned herein, Mr. Oakley has also resigned from his position as Chairman of the Board and his service on the Audit Committee, Compensation Committee and the Nominating and Corporate Governance Committee, and Mr. Meier has also resigned from his service on the Compensation Committee.
Effective on April 23, 2026, the Board has appointed Sammy Dorf, an existing member of the Board, as Chairman of the Board. In connection with Mr. Dorf’s election as Chairman, the Compensation Committee of the Board has agreed to compensate Mr. Dorf $20,000 per year, with $5,000 payable on a quarterly basis, commencing on the date of his election.
Election of Josh Epstein
Effective as of April 23, 2026, the Board elected Josh Epstein to serve as a member of the Board and a member of the Audit Committee, Compensation Committee and as the chair of the Nominating and Corporate Governance Committee. Mr. Epstein, a Class II director, will serve for a term expiring at the Company’s 2026 annual meeting of stockholders.
For his service on the Board, Mr. Epstein will receive compensation consistent with that of other non-employee directors.
February 2026 Special Meeting of Stockholders
On February 3, 2026, the Company held a special meeting of stockholders (the “February 2026 Special Meeting”), whereby its stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (“COI”) to effect a reverse stock split of all of the outstanding shares of Common Stock at a ratio in the range of 1-for-2 to 1-for-50, at any time prior to the one-year anniversary date of the February 2026 Special Meeting (“Reverse Stock Split Proposal”).
On March 6, 2026, the Board determined to fix a reverse stock split ratio of its Common Stock of 1-to-5 (the “March Reverse Stock Split”). On March 24, 2026, the Company filed an amendment to its COI with the Secretary of State of the State of Delaware to effect the March Reverse Stock Split. The March Reverse Stock Split became effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern Time on March 25, 2026 (the “March Reverse Stock Split Effective Time”). The Company’s Common Stock continues to trade on The Nasdaq Capital Market under the symbol ONCO and has been trading on a split-adjusted basis since the market opened on March 25, 2026. At the March Reverse Stock Split Effective Time, every 5 (five) shares of the Company’s issued and outstanding Common Stock had converted automatically into one (1) issued and outstanding share of Common Stock, with no corresponding reduction in the number of authorized shares of Common Stock, and without any change in the par value per share.
34
Realbotix Share Exchange Agreement
On February 11, 2026, we entered into a Share Exchange Agreement, as amended, (the “Share Exchange Agreement”), by and among (i) Onconetix, (ii) Realbotix Corp., a company existing under the laws of the Province of Ontario (“Parent”), (iii) Simulacra Corporation, a Delaware corporation and a wholly-owned subsidiary of Parent (the “Seller”) and (iv) Realbotix, LLC, a Delaware limited liability company and wholly owned subsidiary of the Seller ( “Realbotix”).
Pursuant to the Share Exchange Agreement, subject to the terms and conditions set forth therein, the Seller agreed to contribute and transfer to us, and we agreed to acquire and accept, all of the issued and outstanding equity interests of Realbotix (the “Realbotix Interests”) in exchange for newly issued shares of Common Stock. (the “Share Exchange” and the other transactions contemplated by the Share Exchange Agreement, the “Realbotix Transactions”).
Unless otherwise defined herein, the capitalized terms used below are defined in the Share Exchange Agreement.
On November 4, 2026, the parties entered into the First Amendment to the Share Exchange to, among other things, (i) provide that, if Net Cash is less than $12.5 million and the parties proceed with the Closing, the Seller will own 95% of the Fully Diluted Shares, (ii) provide that Net Cash includes the unpaid principal balance and accrued interest outstanding as of the Closing under the Grid Promissory Note, and (iii) extend the End Date to March 31, 2027. A summary of the terms of the Share Exchange Agreement, as amended, is provided below.
Consideration
In full consideration for the contribution of the Realbotix Interests, we will issue shares of Common Stock to the Seller (the “Exchange Shares”), such that, immediately following the Closing and after giving effect to such issuance, the Seller will own a percentage of our fully diluted shares (the “Fully Diluted Shares”) that will be adjusted based on Net Cash (as defined below) as follows: (i) if Net Cash is less than $12.5 million and the minimum cash condition is waived, Seller will own 95% of the Fully Diluted Shares, (ii) if Net Cash is greater than or equal to $12.5 million, but less than $15.0 million, Seller will own 90% of the Fully Diluted Shares, (iii) if Net Cash is greater than or equal to $15.0 million, but less than $18.0 million, Seller will own 85% of the Fully Diluted Shares, (iv) if Net Cash is greater than or equal to $18.0 million, but less than $20.0 million, Seller will own 80% of the Fully Diluted Shares and (v) if Net Cash is greater than or equal to $20.0 million, Seller will own 75% of the Fully Diluted Shares. “Net Cash” means the amount of cash and cash equivalents held by us upon the Closing, whether received by Realbotix or us in connection with the Realbotix Transactions, plus the unpaid principal balance and accrued interest outstanding under the Grid Promissory Note as of the Closing, net of D&O tail insurance costs; change-of-control, severance or other payments owed to our officers and directors as a result of the Realbotix Transactions; all of our Indebtedness; certain of our liabilities; and our transaction expenses; and amounts relating to the Schedule 3.11 Action.
Conversion of Company Convertible Securities
Prior to the consummation of the Share Exchange, the holders of Realbotix Convertible Securities will exercise their rights to receive Realbotix Interests pursuant to the terms of such Realbotix Convertible Securities (as defined below) at the applicable conversion ratio as set forth in the Realbotix Convertible Securities (the “Realbotix Convertible Securities Conversion”). Upon completion of the Realbotix Convertible Securities Conversion and prior to Closing, all Realbotix Convertible Securities will be canceled or terminated, as applicable, will no longer be outstanding and will cease to exist and no payment or distribution will be made with respect thereto. Each holder of Realbotix Convertible Securities thereafter will cease to have any rights with respect to such securities.
Closing Conditions
The consummation of the Share Exchange is subject to customary closing conditions, including (i) the accuracy of the representations and warranties of the parties (subject to customary materiality qualifiers); (ii) compliance in all material respects by the parties with their respective covenants and agreements under the Share Exchange Agreement; (iii) delivery of customary closing certificates and good standing certificates; (iv) receipt by Board of a fairness opinion; (v) the absence of any law, order or injunction prohibiting the consummation of the Realbotix Transactions and (vi) receipt of any required third-party and regulatory approvals and consents.
The obligation of Realbotix, Parent and Seller to complete the Closing is subject to the condition that, at Closing, we shall have an aggregate of at least $12.5 million in Net Cash, less the unpaid principal balance and accrued interest outstanding under the Grid Promissory Note as of the Closing (the “Net Cash Condition”). If the Net Cash Condition is not satisfied and the Net Cash Condition is waived and the parties proceed with the Closing, the Seller will own 95% of the Fully Diluted Shares.
35
Additionally, the obligation of Realbotix, Parent and us to complete the Closing are subject to the conditions that (i) we have entered into an agreement with an investor, reasonably acceptable to us and Realbotix, providing for an equity line of credit pursuant to which such investor would commit to purchase up to an aggregate of $125.0 million of Common Stock (the “ELOC Condition”) and (ii) the conversion of our Preferred Stock into Common Stock and the termination of or certain amendments to of all Onconetix Options and Onconetix Warrants (the “Convertible Securities Condition”). On July 28, 2026, we entered into the July 2026 ELOC Purchase Agreement with the July 2026 ELOC Investor which is intended to satisfy the ELOC Condition.
Termination
In addition to termination by mutual written agreement, for the other party’s uncured breach or if a governmental order permanently prohibits the Closing, the Share Exchange Agreement provides for termination:
| ● | By either party if the Closing has not been consummated on or before March 31, 2027 (the “End Date”), provided the terminating party is not in breach in a manner that caused the failure to close by such date. |
| ● | By either party if our stockholder approval is not obtained at the stockholder meeting (including any adjournment or postponement thereof). |
| ● | By Realbotix if a Buyer Adverse Recommendation Change (as defined in the Share Exchange Agreement) occurs prior to receipt of Buyer stockholder approval. |
| ● | By us in connection with entering into a definitive agreement for a Buyer Superior Proposal (as defined in the Share Exchange Agreement). |
| ● | By us if the audited Realbotix financial statements were not delivered by April 30, 2026 (they were delivered timely). |
Each party will bear its own fees and expenses incurred in connection with the negotiation, execution and performance of the Share Exchange Agreement and the Realbotix Transactions. However, the Share Exchange Agreement provides for the payment of termination fees and reimbursement of transaction expenses in the following termination scenarios:
| ● | In the event of a termination of the Share Exchange Agreement as a result of a material breach by either party, the breaching party will be required to pay a termination fee to the non-breaching party of $500,000 plus transaction expenses, with such transaction expenses not to exceed $500,000. |
| ● | In the event of a termination of the Share Exchange Agreement (i) by the Company as the result of a Buyer Adverse Recommendation Change or (ii) by Buyer upon entering into an agreement in respect of a Buyer Superior Proposal as a result of a Buyer Adverse Recommendation Change, Buyer must pay a termination fee of (A) $500,000 plus all Seller transaction expenses plus (B) if the transaction in respect of a Buyer Superior Proposal closes, an additional $1,500,000 upon closing of such transaction. If the transaction contemplated by the Buyer Superior Proposal does not close, Buyer is only obligated to pay $500,000 plus all Seller transaction expenses. |
| ● | In the event of a termination of the Share Exchange Agreement by Realbotix for failure to satisfy the Net Cash Condition, if Net Cash at the time of termination would be greater than $5.0 million (assuming the consummation of any Transaction Financing pursuant to Financing Agreements), we are obligated to pay Realbotix’s transaction expenses, with such transaction expenses not to exceed $500,000. |
36
Representations and Warranties
We, Realbotix, and the Seller have made customary representations and warranties in the Share Exchange Agreement. The representations and warranties of us, Realbotix, and the Seller will not survive the Closing.
Covenants of the Parties
Each party to the Share Exchange Agreement agreed to use its commercially reasonable efforts to consummate the Realbotix Transaction.
The Share Exchange Agreement contains certain covenants by each of the parties, to be observed during the period between the execution of the Share Exchange Agreement and Closing, including covenants regarding: (1) the provision of access to information, properties, books, records and personnel; (2) delivery of audited financial statements of the Company; (3) litigation support; (4) the preparation and filing of a registration statement, SEC reports and related disclosure documents and compliance with Nasdaq listing and reporting requirements; (5) no insider trading; (6) further assurances; (7) public announcements; (8) confidentiality; (9) indemnification of directors and officers and tail insurance; and (10) transfer taxes.
The parties have agreed to take all necessary actions to cause our Board, immediately after closing, to consist of five directors, including: (i) one person who is designated by us and reasonably acceptable to Realbotix and (ii) four persons who are designated by Realbotix and reasonably acceptable to us.
We have also agreed to prepare and file with the Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 in connection with the registration under the Securities Act of 1933, as amended (the “Securities Act”), of the issuance of the Exchange Shares to be issued under the Share Exchange Agreement and containing a proxy statement (a “Proxy Statement”) for the purpose of soliciting proxies from our stockholders for the matters to be acted on at the special meeting of our stockholders. We have also agreed to use reasonable best efforts to maintain its listing on the Nasdaq and to enable the listing on Nasdaq of the Exchange Shares.
During the time between the execution of the Share Exchange Agreement and the Closing, Realbotix agreed to conduct its business in the ordinary course of business in all material respects and to comply with certain covenants regarding the operation of its business, including covenants related to (i) amendments to the Realbotix’s organizational documents; (ii) recapitalization of the Realbotix’s equity interests; (iii) issuance of additional securities; (iv) incurrence of additional indebtedness; (v) material changes to tax elections; (vi) amendments to or termination of material contracts; (vii) maintenance of books and records; (viii) establishment of any subsidiary or entry into a new line of business; (ix) maintenance of insurance policies; (x) revaluation of material assets or material changes in accounting methods, principles or policies, except as required to comply with U.S. GAAP; (xi) waiver, settlement or compromise of material claims, actions or proceedings, subject to specified thresholds; (xii) acquisition of equity interests or assets, or any other form of business combination, outside of the ordinary course of business; (xiii) capital expenditures in excess of specified thresholds; (xiv) adoption of a plan of liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization; (xv) voluntary incurrence of liabilities or obligations in excess of specified thresholds other than pursuant to contracts in existence as of the date of the Share Exchange Agreement or entered into in the ordinary course of business; (xvi) sale, lease, license or other disposition of any material portion of the Realbotix’s assets, properties or rights; (xvii) entry into any agreement, understanding or arrangement relating to the voting of the Realbotix’s equity interests; (xviii) taking any action that would reasonably be expected to materially delay or impair the obtaining of any required governmental or regulatory consents in connection with the Share Exchange Agreement; or (xix) authorization or agreement to take any of the foregoing actions.
During the same period, we also agreed to conduct its business in the ordinary course of business in all material respects and to comply with certain interim operating covenants, including covenants restricting our ability, without Realbotix’s prior written consent (subject to specified exceptions), to (i) amend its organizational documents; (ii) effect mergers, consolidations, acquisitions, liquidations, restructurings or other business combinations; (iii) issue, repurchase, redeem or otherwise modify its equity securities or declare dividends or other distributions; (iv) incur additional indebtedness or guarantee obligations of third parties; (v) dispose of material assets or subsidiaries; (vi) make material loans, advances or capital contributions; (vii) make material tax elections or changes in accounting methods, principles or practices, except as required by applicable law, GAAP or Regulation S-K; (viii) amend, terminate, waive or assign material contracts other than in the ordinary course of business; (ix) fail to maintain books, records or insurance coverage in the ordinary course of business; (x) establish subsidiaries or enter into new lines of business; (xi) settle material litigation or other proceedings other than within specified thresholds; (xii) make capital expenditures or incur liabilities in excess of specified thresholds; (xiii) enter into arrangements relating to the voting of Common Stock; (xiv) take actions that would reasonably be expected to materially delay or impair the receipt of required governmental or regulatory approvals; or (xv) authorize, commit or publicly propose any of the foregoing actions.
37
Governing Law
The Share Exchange Agreement is governed by the laws of the State of Delaware.
Series E PIPE Financing
On October 1, 2025, the Company entered into a securities purchase agreement (the “Series E Securities Purchase Agreement”) with institutional investor(s) and sold to such institutional investors(s)(collectively, the “Series E PIPE Investors”), an aggregate of 7,813 shares of Series E convertible preferred stock, par value $0.00001 per share (“Series E Preferred Stock”), which are convertible into common stock of the Company, $0.00001 par value per share and warrants (the “Series E Warrants”) to purchase 4,050 shares of Common Stock, for an aggregate purchase price of approximately $6.25 million, which was also equal to the net cash proceeds. The exercise price of the Series E Warrants is $9.716, and the Series E Warrants are exercisable beginning on the issuance date and expire on the third anniversary of the issuance date.
Concurrently with entering into the Series E Securities Purchase Agreement, the Company also entered into a registration rights agreement with the Series E PIPE Investors, pursuant to which it has agreed to provide the Series E PIPE Investors with certain registration rights related to the shares of Common Stock underlying the shares of Series E Preferred Stock and Series E Warrants.
During the three and nine months ended September 30, 2026, the holders converted 0 and 7,813 shares of Series E Preferred Stock into 0 and 66,803 shares of Common Stock. As of September 30, 2026, all shares of Series E Preferred Stock were converted into Common Stock and there were no Series E Preferred Stock outstanding.
Series D PIPE Financing
On September 22, 2025, the Company entered into a securities purchase agreement (the “Series D Securities Purchase Agreement”) with eleven institutional investors, and sold or exchanged debt, to such investors (collectively, the “Series D PIPE Investors”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“Series D Preferred Stock”), which includes an issuance of 500 shares of Series D Preferred Stock to the lead investor in consideration for the Series D PIPE Investors’ irrevocable commitment to purchase shares of the Series D Preferred Stock, and warrants (the “Series D Warrants”) to purchase 8,725 shares of Common Stock, for an aggregate purchase price of approximately $12.9 million and net cash proceeds of $9.3 million. The exercise price of the Series D Warrants is $9.716, and the Series D Warrants are exercisable beginning on the issuance date and expire on the third anniversary of the issuance date.
Concurrently with entering into the Series D Securities Purchase Agreement, the Company also entered into a registration rights agreement with the Series D PIPE Investors, pursuant to which it has agreed to provide the Series D PIPE Investors with certain registration rights related to the shares of Common Stock underlying the shares of Series D Preferred Stock and Series D Warrants.
During the three and nine months ended September 30, 2026, the holders converted 161 and 8,330 shares of Series D Preferred Stock into 26,179 and 63,777 shares of Common Stock. Additionally, the holders exercised 1,441 warrants for shares of Common Stock, resulting in net proceeds of $385 thousand. As of September 30, 2026, there are 7,995 shares of Series D Preferred Stock outstanding.
Reverse Stock Split
On March 25, 2026, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-five (1:5). The Company accounted for the reverse stock split on a retrospective basis pursuant to Accounting Standards Codification (“ASC”) 260, Earnings Per Share. All issued and outstanding common stock, common stock warrants, and share-based awards’ exercise prices and per share data have been adjusted in these consolidated financial statements, on a retrospective basis, to reflect the reverse stock split for all periods presented. The number of authorized shares and par value of the preferred stock and common stock were not adjusted because of the reverse stock split.
On May 21, 2026, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-ten (1:10). The Company accounted for the reverse stock split on a retrospective basis pursuant to Accounting Standards Codification (“ASC”) 260, Earnings Per Share. All issued and outstanding common stock, common stock warrants, and share-based awards’ exercise prices and per share data have been adjusted in these consolidated financial statements, on a retrospective basis, to reflect the reverse stock split for all periods presented. The number of authorized shares and par value of the preferred stock and common stock were not adjusted because of the reverse stock split.
On November 6, 2026, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-ten (1:10). The Company accounted for the reverse stock split on a retrospective basis pursuant to Accounting Standards Codification (“ASC”) 260, Earnings Per Share. All issued and outstanding common stock, common stock warrants, and share-based awards’ exercise prices and per share data have been adjusted in these consolidated financial statements, on a retrospective basis, to reflect the reverse stock split for all periods presented. The number of authorized shares and par value of the preferred stock and common stock were not adjusted because of the reverse stock split.
38
Certain Significant Relationships
We have entered into grant, license and collaboration arrangements with various third parties as summarized below. For further details regarding these and other agreements, see Note 5 to each of our audited financial statements included in the Form 10-K and unaudited financial statements included elsewhere in this Report.
Laboratory Corporation of America
On March 23, 2023, Proteomedix entered into a license agreement with LabCorp pursuant to which LabCorp has the exclusive right to develop and commercialize Proclarix and other products developed by LabCorp using Proteomedix’s intellectual property covered by the license, in the United States (“Licensed Products” and the agreement, the “LabCorp Agreement”). In consideration for granting LabCorp an exclusive license, Proteomedix received an initial license fee in the mid-six figures upon signing of the contract. Additionally, Proteomedix is entitled to royalty payments between 5% and 10% on the net sales recognized by LabCorp of any Licensed Products plus milestone payments as follows:
| ● | after the first sale of Proclarix as a laboratory developed test, LabCorp will pay an amount in the mid-six figures; |
| ● | after LabCorp achieves a certain amount in the low seven figures in net sales of the Licensed Products, LabCorp will pay Proteomedix an amount in the low seven figures; and |
| ● | after a certain amount in the mid-seven figures in net sales of Licensed Products, LabCorp will pay Proteomedix an amount in the low seven figures. |
A total of $2.5 million in milestone payments are payable under the license agreement. An additional $0.5 million was paid to Proteomedix as an initial license fee in 2023.
LabCorp is wholly responsible for the cost, if any, of research, development and commercialization of Licensed Products in the United States but has the right to offset a portion of those costs against future royalty and milestone payments. Additionally, LabCorp may deduct royalties or other payments made to third parties related to the manufacture or sale of Licensed Products up to a maximum amount of any royalty payments due to Proteomedix.
The license agreement and related royalty payment provisions expire during 2038, which approximates the expiration of the last patent covered by the license agreement. LabCorp has the right to terminate the license agreement for any reason by providing 90 days written notice to Proteomedix. Either party may terminate the license agreement due to a material breach of the terms of the license agreement with 30 days’ notice, provided such breach is not cured within the foregoing 30-day period. Finally, Proteomedix may terminate the license agreement with 60 days’ notice in the event LabCorp fails to make any undisputed payment due, provided that LabCorp does not remit the payment within the foregoing 60-day period.
On December 6, 2025, Proteomedix and LabCorp entered into an amendment (the “LabCorp Amendment”) of the LabCorp License Agreement. The Amendment provides for a new validation study to be conducted by LabCorp for Proclarix, titled Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: A Prospective U.S.-Based Multi-Center Validation Study of Proclarix (the “PRIME Study”). Pursuant to the LabCorp Amendment, LabCorp will not be required to pay any royalties or milestone payments in connection with its use of the risk calculator for purposes of the PRIME Study. The Company will compensate LabCorp with specified milestone-based payments for conducting the PRIME Study of up to $300,000 in the aggregate and will bear all associated costs and expenses. Mid-five figure milestone payments will be made as subjects are enrolled, commencing on the effective date of the PRIME Study and to be paid for every additional batch of subjects enrolled. If the final milestone tier is not reached, the Company must pay Labcorp a fixed amount per subject enrolled beyond the last milestone tier that was paid. All payments are due within thirty (30) days of each invoice.
Pursuant to the LabCorp Amendment, LabCorp is also required to provide the Company with the results of each clinical study conducted by LabCorp upon completion; however, the Company may not use or disclose such results to any third party without LabCorp’s prior consent.
39
Immunovia-Proteomedix Licensing Agreement
On September 17, 2025, Proteomedix entered into a licensing agreement (the “Immunovia Agreement”) with Immunovia, Inc. (“Immunovia”), a pancreatic cancer diagnostics company based in Lund, Sweden. Under the Agreement, Proteomedix will provide Immunovia with master cell lines required to produce antibodies for three of the five biomarkers used in the PancreaSure test, as well as a license to key intellectual property related to the manufacturing of associated reagents.
In return, Immunovia will make total payments of $0.6 million over two payments of $0.3 million each to Proteomedix, due on September 30, 2025 (“Initial Up Front Payment”), and March 31, 2026 (“Second Up Front Payment”). Based on the terms of the agreement and the nature of the license, the Company determined that the performance obligations were satisfied upon the transfer of the licensed rights which occurred during 2025. Accordingly, the Company recognized $0.6 million as license revenue during the year ended December 31, 2025.
Additionally, Immunovia will make a $0.1 million payment for materials and pay a 3% royalty on net sales of PancreaSure and any other products incorporating the licensed intellectual property from January 1, 2026, through December 31, 2032. During the three and nine months ended September 30, 2026, royalty revenues were de minimis and the $0.1 million payment for biological materials was received and recognized as revenue.
Components of Results of Operations
Selling, General and Administrative Expenses
Selling, general and administrative expenses consist principally of commercialization activities, and personnel expenses, including salaries and bonuses, benefits and stock-based compensation expenses, professional fees for legal, consulting, accounting and tax services, information technology costs, costs incurred with respect to acquisitions and potential acquisitions, and other general operating expenses.
We anticipate that our selling, general and administrative expenses related to Proteomedix will increase when compared to historical levels as a result of efforts to commercialize Proclarix, and costs associated with integration of Proteomedix’s operations.
Research and Development Expenses
Historically, substantially all of our research and development expenses consist of expenses incurred in connection with the development of our product candidates. These expenses historically have included fees paid to third parties to conduct certain research and development activities on our behalf, consulting costs, costs for laboratory supplies, product acquisition and license costs, certain payroll, and personnel-related expenses, including salaries and bonuses, employee benefit costs and stock-based compensation expenses for our research and product development employees. We expense both internal and external research and development expenses as they are incurred.
We do not allocate our costs by product candidate, as a significant amount of research and development expenses include internal costs, such as payroll and other personnel expenses, laboratory supplies, and external costs, such as fees paid to third parties to conduct research and development activities on our behalf, that are not tracked by product candidate.
As discussed above, we have terminated the vaccine programs that substantially all of our research and development historically related to. We do not anticipate incurring significant research and development expenses in the near future, unless we are able to resume such activities. Predicting the timing or cost to complete our clinical programs for future product candidates, or validation of our commercial manufacturing and supply processes is difficult and delays may occur because of many factors, including factors outside of our control, such as regulatory approvals. Furthermore, we are unable to predict when or if our future product candidates will receive regulatory approval with any certainty.
40
Other Income (Expense)
Other income (expense) is comprised of interest expense on notes payable, the change in fair value of financial instruments that are recorded as liabilities, which includes the related party subscription agreement liability, the contingent warrant liabilities, derivative liabilities, and other financing-related costs.
Results of Operations
Comparison of the Three Months Ended September 30, 2026 and 2025
The following table summarizes our statements of operations for the periods indicated:
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | $ Change | % Change | |||||||||||||
| Revenue | $ | 102,884 | $ | 303,651 | $ | (200,767 | ) | (66.1 | )% | |||||||
| Cost of revenue | 24,718 | 34,757 | (10,039 | ) | (28.9 | )% | ||||||||||
| Gross profit | 78,166 | 268,894 | (190,728 | ) | (70.9 | )% | ||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | $ | 1,478,206 | $ | 2,341,347 | $ | (863,141 | ) | (36.9 | )% | |||||||
| Research and development | 6,233 | (3,211 | ) | 9,444 | 294.1 | % | ||||||||||
| Total operating expenses | 1,484,439 | 2,338,136 | (853,697 | ) | (36.5 | )% | ||||||||||
| Loss from operations | (1,406,273 | ) | (2,069,242 | ) | 662,969 | 32.0 | % | |||||||||
| Other income (expense) | ||||||||||||||||
| Loss on extinguishment of note payable | — | (5,384,719 | ) | 5,384,719 | 100.0 | % | ||||||||||
| Loss on issuance of preferred stock and warrants | — | (2,543,329 | ) | 2,543,329 | 100.0 | % | ||||||||||
| Loss on extinguishment of preferred stock | — | (196,244 | ) | 196,244 | 100.0 | % | ||||||||||
| Interest expense | (3,246 | ) | (300,069 | ) | 296,823 | 98.9 | % | |||||||||
| Change in fair value of contingent warrant liabilities | (600 | ) | (36 | ) | (564 | ) | (1566.7 | )% | ||||||||
| Change in fair value of Series D Derivative Liability | 89,303 | (216,000 | ) | 305,303 | 141.3 | % | ||||||||||
| Change in fair value of Series F Derivative Liability | 70,329 | — | 70,329 | 100.0 | % | |||||||||||
| Change in fair value of Series D Warrant Liability | — | 1,934,000 | (1,934,000 | ) | (100.0 | )% | ||||||||||
| ELOC commitment fee | (30,391,400 | ) | — | (30,391,400 | ) | (100.0 | )% | |||||||||
| Other income (loss) | 13,956 | (8,063 | ) | 22,019 | 273.1 | % | ||||||||||
| Total other expense | (30,221,658 | ) | (6,714,460 | ) | (23,507,198 | ) | (350.1 | )% | ||||||||
| Loss before income taxes | (31,627,931 | ) | (8,783,702 | ) | (22,844,229 | ) | (260.1 | )% | ||||||||
| Net loss | $ | (31,627,931 | ) | $ | (8,783,702 | ) | $ | (22,844,229 | ) | (260.1 | )% | |||||
Revenue, Cost of Revenue, and Gross Margin
For the three months ended September 30, 2026, the Company generated approximately $0.1 million of revenue, compared to approximately $0.3 million for the same period in 2025. Revenue for the three months ended September 30, 2026 consisted primarily of a sale of Proclarix materials to Immunovia by Proteomedix. Revenue for the same period in 2025 consisted primarily of approximately $0.3 million of license revenue recognized under the Immunovia license agreement (see Note 5). Accordingly, the decrease in revenue was primarily attributable to the non-recurring nature of the Immunovia license and materials revenue rather than a decline in product sales. Cost of revenue for the three months ended September 30, 2026 was approximately $0.02 million, compared to approximately $0.03 million for the same period in 2025, and consisted primarily of the cost of materials sold to Immunovia. Gross profit decreased to approximately $0.08 million for the three months ended September 30, 2026, compared to approximately $0.27 million for the same period in 2025. Gross margin decreased from approximately 88.6% to 76.0%, primarily due to the fact that revenue for the three months ended September 30, 2025 consisted mainly of license revenue with minimal associated cost of revenue, while revenue for the three months ended September 30, 2026 consisted mainly of a materials sale with direct material costs.
Selling, General and Administrative Expenses
For the three months ended September 30, 2026, selling, general and administrative expenses decreased by approximately $0.9 million compared to the same period in 2025. The decrease was primarily attributable to lower professional fees, legal expenses, and costs associated with financing and strategic transaction activities incurred during the prior-year period.
41
Research and Development Expenses
For the three months ended September 30, 2026, research and development expenses increased by approximately $9 thousand to approximately $6 thousand compared to a gain of approximately $3 thousand in the same period in 2025. The gain during the three months ended September 30, 2025 resulted from the write-off of previously accrued R&D expenses that were related to terminated contracts. The expense during the three months ended September 30, 2026 related to the new clinical study agreement with LabCorp where the Company agreed to pay for research and development costs.
Other Expense
Other expense for the three months ended September 30, 2026 increased by approximately $23.5 million compared to the same period in 2025. The increase was primarily attributable to $30.4 million of commitment fee expense from the July 2026 ELOC Purchase Agreement and the absence of approximately $1.9 million of gains from changes in the fair value of Series D warrant liabilities recognized in the prior-year period, partially offset by the absence of approximately $5.4 million of loss on extinguishment of notes payable, $2.5 million of loss on issuance of preferred stock and warrants recognized in the prior-year period, and $0.4 million increase in the gain on change in fair value of Series D and F Preferred Stock derivative liability.
Income Tax Benefit
The Company did not record any income tax benefit or expense during the three months ended September 30, 2026 and 2025.
Comparison of the Nine Months Ended September 30, 2026 and 2025
The following table summarizes our statements of operations for the periods indicated:
| Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | $ Change | % Change | |||||||||||||
| Revenue | $ | 141,461 | $ | 511,775 | $ | (370,314 | ) | (72.4 | )% | |||||||
| Cost of revenue | 60,647 | 126,546 | (65,899 | ) | (52.1 | )% | ||||||||||
| Gross profit | 80,814 | 385,229 | (304,415 | ) | (79.0 | )% | ||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | $ | 5,763,187 | $ | 5,539,144 | $ | 224,043 | 4.0 | % | ||||||||
| Research and development | 60,491 | (90,426 | ) | 150,917 | 166.9 | % | ||||||||||
| Impairment of goodwill | 8,620,000 | 11,512,000 | (2,892,000 | ) | (25.1 | )% | ||||||||||
| Total operating expenses | 14,443,678 | 16,960,718 | (2,517,040 | ) | (14.8 | )% | ||||||||||
| Loss from operations | (14,362,864 | ) | (16,575,489 | ) | 2,212,625 | 13.3 | % | |||||||||
| Other income (expense) | ||||||||||||||||
| Loss on extinguishment of note payable | — | (5,384,719 | ) | 5,384,719 | 100.0 | % | ||||||||||
| Loss on issuance of preferred stock and warrants | — | (2,543,329 | ) | 2,543,329 | 100.0 | % | ||||||||||
| Loss on extinguishment of preferred stock | — | (196,244 | ) | 196,244 | 100.0 | % | ||||||||||
| Interest expense | (9,879 | ) | (746,758 | ) | 736,879 | 98.7 | % | |||||||||
| Change in fair value of subscription agreement liability – related party | — | 3,127,962 | (3,127,962 | ) | (100.0 | )% | ||||||||||
| Change in fair value of contingent warrant liabilities | 612 | (10,060 | ) | 10,672 | 106.1 | % | ||||||||||
| Change in fair value of Series D Derivative Liability | 3,908,610 | (216,000 | ) | 4,124,610 | 1909.5 | % | ||||||||||
| Change in fair value of Series E Derivative Liability | 2,072,590 | — | 2,072,590 | 100.0 | % | |||||||||||
| Change in fair value of Series F Derivative Liability | 70,329 | — | 70,329 | 100.0 | % | |||||||||||
| Change in fair value of Series D Warrant Liability | — | 1,934,000 | (1,934,000 | ) | (100.0 | )% | ||||||||||
| ELOC commitment fee | (30,391,400 | ) | — | (30,391,400 | ) | (100.0 | )% | |||||||||
| Gain on forgiveness of accounts payable | — | 944,694 | (944,694 | ) | (100.0 | )% | ||||||||||
| Other income (loss) | 1,893 | (36,086 | ) | 37,979 | 105.2 | % | ||||||||||
| Total other expense | (24,347,245 | ) | (3,126,540 | ) | (21,220,705 | ) | (678.7 | )% | ||||||||
| Loss before income taxes | (38,710,109 | ) | (19,702,029 | ) | (19,008,080 | ) | (96.5 | )% | ||||||||
| Net loss | $ | (38,710,109 | ) | $ | (19,702,029 | ) | $ | (19,008,080 | ) | (96.5 | )% | |||||
| Deemed dividend Series C preferred stock | — | (1,498,595 | ) | 1,498,595 | 100.0 | % | ||||||||||
| Net loss applicable to common stockholders’ | $ | (38,710,109 | ) | $ | (21,200,624 | ) | $ | (17,509,485 | ) | (82.6 | )% | |||||
42
Revenue, Cost of Revenue, and Gross Margin
For the nine months ended September 30, 2026, the Company generated approximately $0.14 million of revenue as compared to approximately $0.51 million for the same period in 2025. Revenue for the nine months ended September 30, 2026 consisted of approximately $0.1 million from a sale of Proclarix materials to Immunovia and approximately $0.04 million of Proclarix product sales to laboratory customers. Revenue for the same period in 2025 consisted primarily of approximately $0.3 million of Immunovia license revenue (see Note 5) and approximately $0.2 million of Proclarix assay sales to Immunovia. The decrease in revenue was primarily attributable to lower non-recurring Immunovia license and materials revenue. Product sales to other customers increased slightly compared to the prior-year period. Cost of revenue was approximately $0.06 million, compared to approximately $0.13 million for the same period in 2025. Gross profit decreased to approximately $0.08 million from approximately $0.39 million, and gross margin decreased from approximately 75.3% to 57.1%, primarily due to the absence of license revenue, which has minimal cost of revenue, in the current period.
Selling, General and Administrative Expenses
For the nine months ended September 30, 2026, selling, general and administrative expenses increased by approximately $0.2 million compared to the same period in 2025. The increase was primarily attributable to higher professional fees, legal expenses, and costs associated with financing and strategic transaction activities incurred during the current year period.
Research and Development Expenses
For the nine months ended September 30, 2026, research and development expenses increased by approximately $0.2 million from a gain of approximately $0.1 million during the nine months ended September 30, 2025 to expense of approximately $0.1 million during the nine months ended September 30, 2026. The expense during the nine months ended September 30, 2026 related to the new clinical study agreement with LabCorp where the Company agreed to pay for research and development costs. The gain during the nine months ended September 30, 2025 resulted from the write-off of previously accrued R&D expenses that were related to terminated contracts.
Impairments
The Company recorded an impairment of goodwill related to the PMX acquisition during the nine months ended September 30, 2026 totaling $8.6 million, compared to $11.5 million during the nine months ended September 30, 2025.
Other Expense
Other expense for the nine months ended September 30, 2026 increased by approximately $21.2 million compared to the same period in 2025. The increase was primarily attributable to approximately $30.4 million of commitment fee expense from the July 2026 ELOC Purchase Agreement, the absence of approximately $3.1 million of gain from the change in fair value of the subscription agreement liability recognized in the prior-year period, the absence of approximately $1.9 million of gain from the change in fair value of the Series D warrant liability recognized in the prior-year period, and the absence of approximately $0.9 million of gain on forgiveness of accounts payable recognized in the prior-year period. These unfavorable changes were partially offset by increases in gains of approximately $4.1 million, $2.1 million and $0.1 million related to changes in the fair value of the Series D, Series E and Series F derivative liabilities, respectively, and the absence of approximately $5.4 million of loss on extinguishment of notes payable and $2.5 million of loss on issuance of preferred stock and warrants recognized in the prior-year period.
Income Tax Benefit
The Company did not record any income tax benefit or expense during the nine months ended September 30, 2026 and 2025.
Liquidity and Capital Resources
The Company’s operating activities to date have been primarily devoted to seeking licenses, engaging in research and development activities, potential asset and business acquisitions, and expenditures associated with the now halted commercial launch of ENTADFI and the commercialization of Proclarix.
The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future.
As of September 30, 2026, the Company had cash of approximately $2.7 million, a working capital surplus of approximately $1.9 million and an accumulated deficit of approximately $169.9 million. During the nine months ended September 30, 2026, the Company used approximately $5.8 million in cash for operating activities. The Company believes its current cash balance is not sufficient to fund its operations for the next twelve months after the date of this Report.
During the financial year ended December 31, 2025, the Company closed the Series D Preferred Stock financing in September 2025 and the Series E Preferred Stock financing in October 2025 which provided the Company with additional cash flow to support near-term operations.
43
During July 2026, the Company entered into the Series F Preferred Stock financing and the July 2026 ELOC Purchase Agreement. The Series F Preferred Stock financing generated net proceeds of $134,597 to the Company after transactions costs of $115,003. The July 2026 ELOC Purchase Agreement may provide additional liquidity, subject to the terms, conditions and limitations of the agreement.
In connection with the proposed Realbotix Transaction, the Company agreed to provide interim financing to Realbotix, LLC under a grid promissory note (the “Grid Promissory Note”), which permits advances of up to $5.0 million in aggregate. On September 11, 2026, the Company advanced $2.5 million to Realbotix under the Grid Promissory Note. Subsequent to September 30, 2026, on October 22, 2026, the Company advanced an additional $0.5 million, and up to $2.0 million remains available to Realbotix under the Grid Promissory Note. The Grid Promissory Note is an unsecured obligation of Realbotix. The Grid Promissory Note matures on September 11, 2027 and does not bear interest prior to the earlier of the closing of the Share Exchange, or the termination of the Share Exchange Agreement. If the Share Exchange Agreement is terminated, interest will accrue on the outstanding principal balance at a rate of 12% per annum until the Grid Promissory Note is paid. Advances under the Grid Promissory Note reduce the cash available to fund the Company’s operations, and repayment depends on Realbotix’s ability to repay or on completion of the Realbotix Transaction. These advances and the remaining funding commitment were considered in management’s evaluation of the Company’s ability to continue as a going concern.
Management’s plans for funding the Company’s operations include generating product revenue from sales of Proclarix, which is still subject to further successful commercialization activities within certain jurisdictions. Management also intends to secure additional funding through equity or debt financings if available, and to utilize the ELOC agreement entered into in October 2024 (the “October 2024 ELOC Purchase Agreement”) and the July 2026 ELOC Purchase Agreement (both ELOC agreements, the “ELOC Agreements”) on an as-needed basis to fund current operating needs, including future expenses incurred in connection with closing the Share Exchange Agreement, subject to certain restrictions and beneficial ownership constraints. However, based on the terms of the ELOC Agreements and their current maximum availability to be drawn upon, management determined that the funds readily available under the ELOC Agreements will not be sufficient to sustain operations. In addition, there are currently no other commitments in place for further financing nor is there any assurance that such financing will be available to sustain its operations and expand commercialization of Proclarix. If the Company is unable to secure additional capital, it may be required to curtail any future clinical trials, development and/or commercialization of Proclarix and any future product candidates, or it may be unable to close the Realbotix Transactions on a timely basis as contemplated in the Share Exchange Agreement. As such, the Company may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations, or, if it is required to, file for bankruptcy.
Because of historical and expected operating losses, net operating cash flow deficits, and debts due within one year, there is substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the consolidated financial statements, which is not alleviated by management’s plans. The consolidated financial statements have been prepared assuming the Company will continue as a going concern. These consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.
Future Funding Requirements
We anticipate that we will continue to incur significant expenses for the foreseeable future as we continue to commercialize Proclarix and to close the Realbotix Transactions as contemplated in the Share Exchange Agreement.
We will require significant amounts of additional capital in the short-term, to continue to fund our continuing operations, to close the Realbotix Transactions, to satisfy existing and future obligations and liabilities under contracts entered into in support of the Company’s commercialization plans, in addition to funds needed to support our working capital needs and business activities, including the development and commercialization of Proclarix, and the development and commercialization of our future product candidates. Until we can generate a sufficient amount of revenue from sales of Proclarix if at all, we expect to finance our future cash needs through public or private equity or debt financings, third-party funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches.
Management also continues to evaluate additional financing opportunities, including remaining availability under the ELOC Agreements, subject to applicable limitations and conditions. This creates significant uncertainty whether the Company will have the funds available to be able to sustain its operations and expand commercialization of Proclarix, or to close the Realbotix Transactions on a timely basis as contemplated in the Share Exchange Agreement. If the Company is unable to secure additional capital, it may be required to curtail any future clinical trials, development and/or commercialization of future product candidates, delay the closing of or terminate the proposed Realbotix Transactions as contemplated in the Share Exchange Agreement, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations, or, if it’s required to, file for bankruptcy.
Our future capital requirements will depend on many factors, including:
| ● | fees paid to financial, legal, accounting and other advisors in connection with negotiating and completing the Realbotix Transactions; | |
| ● | the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties, and distribution, for Proclarix, and other products for which we may receive marketing approval; |
44
| ● | the timing, scope, progress, results and costs of research and development, testing, screening, manufacturing, preclinical and non-clinical studies and clinical trials; | |
| ● | the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform field efficacy studies, require more studies than those that we currently expect or change their requirements regarding the data required to support a marketing application; |
| ● | our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; | |
| ● | any product liability or other lawsuits related to our product; | |
| ● | the expenses needed to attract, hire and retain skilled personnel; | |
| ● | the revenue, if any, received from commercial sales of Proclarix, or other products for which we may have received or will receive marketing approval; | |
| ● | the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing our patents or other intellectual property rights; and | |
| ● | the costs of operating as a public company. |
A change in the outcome of any of these or other variables could significantly change the costs and timing associated with our business activities. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such change.
Cash Flows
The following table summarizes our cash flows for the periods indicated:
| Nine months Ended September 30, 2026 | Nine months Ended September 30, 2025 | |||||||
| Net cash used in operating activities | $ | (5,758,516 | ) | $ | (6,587,805 | ) | ||
| Net cash used in investing activities | (2,500,000 | ) | — | |||||
| Net cash provided by financing activities | 5,876,699 | 7,905,978 | ||||||
| Effect of exchange rate changes on cash | (97,180 | ) | (1,128,117 | ) | ||||
| Net increase (decrease) in cash | $ | (2,478,997 | ) | $ | 190,056 | |||
Cash Flows from Operating Activities
Net cash used in operating activities for the nine months ended September 30, 2026, was approximately $5.8 million. This was primarily driven by a net loss of approximately $38.7 million, gains on changes in the fair value of derivative liabilities of approximately $6.1 million, and net changes in operating assets and liabilities of approximately $0.1 million. Such items were partially offset by non-cash charges, including the commitment fee from the July 2026 ELOC Purchase Agreement of approximately $30.4 million, a loss on impairment of goodwill of approximately $8.6 million, Series F Preferred Stock Financing expenses paid of approximately $0.05 million, stock-based compensation expense of approximately $0.03 million, and depreciation and amortization of approximately $0.01 million.
Net cash used in operating activities for the nine months ended September 30, 2025, was approximately $6.6 million, which primarily resulted from a net loss of approximately $19.7 million, a non-cash change in fair value of subscription liability of approximately $3.1 million, a gain on forgiveness of accounts payable of approximately $0.9 million, a non-cash change in fair value of Series D warrant liability of approximately $1.9 million, and net changes in our operating assets and liabilities of $1.3 million. These items were offset by several non-cash items, which primarily include impairment of goodwill of approximately $11.5 million, loss on extinguishment of notes payable of approximately $5.4 million, and loss on issuance of Series D preferred stock of approximately $2.5 million.
Cash Flows from Investing Activities
Net cash used in investing activities during the nine months ended September 30, 2026 was $2.5 million, primarily attributable to an advance made under the Grid Promissory Note.
45
Cash Flows from Financing Activities
Net cash provided by financing activities for the nine months ended September 30, 2026, was approximately $5.9 million, and resulted primarily from proceeds of approximately $5.2 million from the purchase of common stock, proceeds of approximately $0.4 million from exercise of warrants, proceeds from the issuance of Series F Preferred stock of approximately $0.2 million, outflows of $(0.1) million for transaction costs – Series F Preferred stock, proceeds of approximately $0.2 million from notes payable, and partially offset by payments of note payable of $0.2 million.
Net cash provided by financing activities for the nine months ended September 30, 2025, was approximately $7.9 million, and resulted primarily from proceeds of approximately $9.3 million from the issuance proceeds of Series D preferred stock and warrants, $6.4 million from the purchase of Common Stock in connection with the October 2024 ELOC Purchase Agreement and $0.9 million from the issuance of notes payable. These proceeds were offset by payments on notes payable of approximately $6.9 million and a payment of approximately $1.7 million related to redemption of the Series C Preferred Stock.
Legal Contingencies
From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated.
Off-Balance Sheet Arrangements
During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined in the rules and regulations of the SEC.
Recent Accounting Pronouncements Not Yet Adopted
See Note 3 to our condensed consolidated financial statements included elsewhere in this Report for more information.
Critical Accounting Policies and Estimates
Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Our critical accounting policies and estimates are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates,” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 13, 2026. Except as described below, there have been no material changes to them during the nine months ended September 30, 2026.
Series F Preferred Stock and ELOC Commitment Fee
On July 28, 2026, we issued 37,812 shares of Series F Preferred Stock for cash of $0.2 million and an investor’s commitment to purchase shares of our common stock under the July 2026 ELOC Purchase Agreement. Accounting for this transaction required significant estimates and judgments in the following areas:
(1) Fair value of the Series F Preferred Stock and commitment fee for the July 2026 ELOC Purchase Agreement. Management, with the assistance of an independent valuation specialist using a Monte Carlo simulation, estimated the fair value of the Series F Preferred Stock at issuance at $30.6 million. The right under the July 2026 ELOC Purchase Agreement did not meet the definition of an asset. We therefore recognized the excess of that fair value over the cash received, $30.4 million, as commitment fee expense for the July 2026 ELOC Purchase Agreement in other income (expense). The most significant assumption was the probability of closing the proposed Realbotix Transaction, which we estimated at 40% at issuance. Other significant assumptions were a common stock price of $8.30, expected volatility of 150% and risk-free rates of 3.90% to 4.26%. Each 10 percentage point increase or decrease in the assumed closing probability would have increased or decreased the fair value, and the related expense, by approximately $2.6 million.
(2) Embedded derivative. We concluded that certain conversion, redemption and change-of-control features of the Series F Preferred Stock must be bifurcated and accounted for as a single derivative liability. The derivative was recognized at an estimated fair value of $1.6 million and is remeasured to fair value each reporting period, with changes recognized in earnings. At September 30, 2026, its fair value was $1.5 million, reflecting a 49% closing probability, a stock price of $7.80, expected volatility of 150% and a risk-free rate of 4.13%. We recognized a gain of $0.1 million for the period. These inputs are unobservable, and changes in them, especially the probability of closing the Realbotix Transaction and our stock price, could produce material gains or losses in future periods.
46
(3) Temporary equity. The Series F Preferred Stock may become redeemable for cash in circumstances outside our control, including if we do not have sufficient authorized shares of common stock under our certificate of incorporation to satisfy conversions. As a result, the Series F Preferred Stock is classified in temporary equity. We have concluded that redemption is not currently probable, and accordingly, we have not remeasured the Series F Preferred Stock to its redemption value. If redemption of the Series F Preferred Stock becomes probable, we would remeasure it to its redemption value, which would increase net loss attributable to common stockholders and could be material.
JOBS Act
Section 107 of the Jumpstart Our Business Startups Act (“JOBS”) Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period.
For as long as we remain an “emerging growth company” under the JOBS Act, we will, among other things:
| ● | be exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act, which requires that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting; |
| ● | be permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and instead provide a reduced level of disclosure concerning executive compensation; and |
| ● | be exempt from any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor’s report on the financial statements. |
We currently intend to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to us so long as we qualify as an “emerging growth company,” including the extension of time to comply with new or revised financial accounting standards available under Section 102(b) of the JOBS Act. Among other things, this means that our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an emerging growth company, which may increase the risk that weaknesses or deficiencies in our internal control over financial reporting go undetected. Likewise, so long as we qualify as an emerging growth company, we may elect not to provide you with certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. As a result, investor confidence in our company and the market price of our common stock may be materially and adversely affected.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a smaller reporting company, we are not required to provide the information required by this Item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the appropriate time periods, and that such information is accumulated and communicated to the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer has evaluated the effectiveness of our disclosure controls and procedures. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer has concluded that the Company’s disclosure controls and procedures were not effective as of September 30, 2026, as a result of the material weaknesses described below.
Material Weaknesses in Internal Control Over Financial Reporting
A material weakness in internal control is a deficiency in internal control, or combination of control deficiencies, that adversely affects the Company’s ability to initiate, authorize, record, process, or report external financial data reliably in accordance with GAAP such that there is more than a remote likelihood that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected.
We have identified the following internal control deficiencies, which we believe to be material weaknesses as of September 30, 2026:
| ● | We did not maintain an effective control environment as there was an inadequate segregation of duties with respect to certain cash disbursements. |
47
| ● | We do not have an effective risk assessment process and effective monitoring of compliance with established accounting policies and procedures, and do not demonstrate a sufficient level of precision in the application of our controls. |
| ● | Our controls over the approval and reporting of expense payments were not designed and maintained to achieve the Company’s objectives. |
| ● | We do not yet have adequate internal controls in place for the timely identification, approval or reporting of related party transactions. |
| ● | We have insufficient accounting resources to maintain adequate segregation of duties, maintain adequate controls over the approval and posting of journal entries, and to provide optimal levels of oversight in order to process financial information in a timely manner, analyze and account for complex, non-routine transactions, and prepare financial statements. |
| ● | The Company did not design, implement and maintain effective controls to ensure information technology (“IT”) policies and procedures set the tone at the top, to mitigate the risks to the achievement of IT objectives and Information Technology General Controls (ITGCs) in the change management, logical security and computer operations domains. Specifically, the design and implementation of user authentication, user access privileges, data backup and data recovery controls as well as the monitoring controls of excessive user access and elevated privileged access to financial applications and data were not appropriately designed and maintained. In addition, these inadequate ITGC controls combined with the use of personal devices to conduct business, can lead to an IT control environment vulnerable to breaches and social engineering persuasion. |
The above material weaknesses did not result in a material misstatement of our previously issued financial statements but could have resulted in material misstatements of our account balances or disclosures of our annual or interim financial statements that would not be prevented or detected. We have developed a remediation plan for these material weaknesses which is described below in Remediation of Material Weaknesses.
Remediation of Material Weaknesses
As of the date of this Quarterly Report on Form 10-Q, management is re-assessing the design of controls and modifying processes designed to improve our internal control over financial reporting and remediate the control deficiencies that led to the material weaknesses, including but not limited to (a) improving consistency in change management supported by standard operating procedures to govern the authorization, testing and approval of changes to information technology systems supporting all of the Company’s internal control processes, (b) enhancing design and implementation of our control environment, including the expansion of formal accounting and IT policies and procedures and financial reporting controls, (c) continuing to identify and design and implement effective review and approval controls, and (d) implementing appropriate timely review and oversight responsibilities within the accounting and financial reporting functions and ensuring appropriate segregation of duties.
We will consider the material weaknesses remediated after the applicable controls operate for a sufficient period of time, and management has concluded, through testing, that the controls are operating effectively.
The process of designing and implementing an effective accounting and financial reporting system is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain an accounting and financial reporting system that is adequate to satisfy our reporting obligations. As we continue to evaluate and take actions to improve our internal control over financial reporting, we may determine to take additional actions to address control deficiencies or determine to modify certain of the remediation measures described above. We cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to remediate the material weakness we have identified or avoid potential future material weaknesses.
Inherent Limitation on the Effectiveness of Internal Control Processes
Our Chief Executive Officer and Chief Financial Officer does not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Changes in Internal Control over Financial Reporting
During the fiscal quarter ended September 30, 2026, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
48
PART II – OTHER INFORMATION
Item 1. Legal Proceedings
We are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us or any of our officers or directors in their corporate capacity.
Item 1A. Risk Factors
We are a smaller reporting company and accordingly we are not required to provide information required by this Item. The risk factors that may affect our business and financial results are discussed in our Annual Report on Form 10-K, filed with the SEC on March 13, 2026, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we have filed or will file with the SEC. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
There are no transactions that have not been previously included in a Current Report on Form 8-K.
Issuer Purchases of Equity Securities
None.
Item 3. Default Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
49
Item 6. Exhibits
The following documents are filed as exhibits to this Report.
EXHIBIT INDEX
| Incorporated by Reference | ||||||||
| Exhibit No. | Description | Form | Exhibit | Filing Date | ||||
| 2.1 | Share Exchange Agreement, dated February 11, 2026, by and among Onconetix, Inc., Realbotix, LLC, Realbotix Corp, and Simulacra Corporation.† | 8-K | 2.1 | February 12, 2026 | ||||
| 3.1 | Amended and Restated Certificate of Incorporation filed with Delaware Secretary of State dated February 23, 2022 | 8-K | 3.1 | February 24, 2022 | ||||
| 3.2 | Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation, dated April 24, 2023 | 8-K | 3.1 | April 24, 2023 | ||||
| 3.3 | Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation, dated December 21, 2023 | 8-K | 3.1 | December 21, 2023 | ||||
| 3.4 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024 | 8-K | 3.1 | September 24, 2024 | ||||
| 3.5 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated June 11, 2025 | 8-K | 3.1 | June 11, 2025 | ||||
| 3.6 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc. dated March 25, 2026 | 8-K | 3.1 | March 27, 2026 | ||||
| 3.7 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc. dated May 20, 2026 | 8-K | 3.1 | May 19, 2026 | ||||
| 3.8 | Fourth Amended and Restated Bylaws of the Company | 8-K | 3.2 | December 21, 2023 | ||||
| 3.9 | Certification of Designation of Series C Preferred Stock. | 8-K | 3.1 | October 3, 2024 | ||||
| 3.10 | Certificate of Correction to Certificate of Designations authorizing the issuance of the Series C Preferred Stock | 10-Q | 3.7 | June 12, 2025 | ||||
| 3.11 | Certification of Designation of Series D Preferred Stock. | 8-K | 3.1 | September 26, 2025 | ||||
| 3.12 | Certification of Designation of Series F Preferred Stock. | 8-K | 3.1 | July 29, 2026 | ||||
| 4.1 | Form of Inducement PIO | 8-K | 4.1 | July 11, 2024 | ||||
| 4.2 | Form of Warrant (Series C) | 8-K | 4.1 | October 3, 2024 | ||||
| 4.3 | Form of Warrant (Series D) | 8-K | 4.1 | September 26, 2025 | ||||
| 4.4 | Form of Warrant (Series E) | 8-K | 4.1 | October 3, 2025 | ||||
| 10.1 | Common Stock Purchase Agreement, between the Company and the July 2026 ELOC Investor, dated July 28, 2026 | 8-K | 10.3 | July 29, 2026 | ||||
| 10.2 | Registration Rights Agreement, between the Company and the July 2026 ELOC Investor, dated July 28, 2026 | 8-K | 10.4 | July 29, 2026 | ||||
| 10.3 | Form of Grid Promissory Note, dated September 11, 2026, by and between Realbotix, LLC and Onconetix, Inc. | 8-K | 10.1 | September 14, 2026 | ||||
| 10.4 | Form of Guaranty of Payment, dated September 11, 2026, by Realbotix Corp. in favor of Onconetix, Inc. | 8-K | 10.2 | September 14, 2026 | ||||
| 31.1* | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||||||
| 31.2* | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||||||
| 32.1** | Certification of the Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||||
| 32.2** | Certification of the Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||||
| 101.INS* | Inline XBRL Instance Document. | |||||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |||||||
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||||||
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||||||
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | |||||||
| * | Filed herewith. |
| ** | Furnished herewith. |
| † | Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. |
50
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Onconetix, Inc. | |
| Date: November 16, 2026 | /s/ David A. White |
| David A. White | |
| Chief Executive Officer (principal executive officer) |
51